Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter Trypanosoma brucei by Alghamdi, Ali et al.
 1 
Positively selected modifications in the pore of TbAQP2 allow pentamidine to enter 1 
Trypanosoma brucei  2 
 3 
Ali H. Alghamdi
1
, Jane C. Munday
1
, Gustavo D. Campagnaro
1
, Dominik Gurvič2, Fredrik 4 
Svensson
3
, Chinyere E. Okpara
4
, Arvind Kumar ,
5
 Juan F. Quintana,
6
 Maria Esther Martin 5 
Abril
1
, Patrik Milić1, Laura Watson1, Daniel Paape,1 Luca Settimo,1 Anna Dimitriou1, Joanna 6 
Wielinska
1
, Graeme Smart
1
, Laura F. Anderson
1
, Christopher M. Woodley,
4
 Siu Pui Ying 7 
Kelley
1
, Hasan M.S. Ibrahim
1
, Fabian Hulpia
7
 , Mohammed I. Al-Salabi
1
, Anthonius A. Eze
1
, 8 
Ibrahim A. Teka
1
, Simon Gudin
1
, Mark C. Field,
6
 Christophe Dardonville
8
, Richard R 9 
Tidwell
9
, Mark Carrington
10
, Paul M. O’Neill4, David W Boykin5, Ulrich Zachariae2, Harry 10 
P. De Koning
1,*
  11 
 12 
1. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 13 
8TA, UK 14 
2. Computational Biology Centre for Translational and Interdisciplinary Research, 15 
University of Dundee, Dundee DD1 5EH, UK 16 
3. IOTA Pharmaceuticals Ltd, St Johns Innovation Centre, Cowley Road, Cambridge CB4 17 
0WS 18 
4. Department of Chemistry, University of Liverpool, Liverpool, UK 19 
5. Chemistry Department, Georgia State University, Atlanta, GA, US  20 
6.  School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK 21 
7. Laboratory for Medicinal Chemistry, University of Ghent, Ghent, Belgium 22 
8. Instituto de Química Médica - CSIC, Madrid, Spain 23 
9. Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, 24 
Chapel Hill, NC, USA 25 
 2 
10. Department of Biochemistry, University of Cambridge, Cambridge, UK 26 
 27 
*, to whom correspondence should be addressed:  28 
email: Harry.de-Koning@glasgow.ac.uk  29 
tel: +44-141-3303753 30 
 31 
Running title : Mechanism of drug transport by TbAQP2  32 
 3 
Abstract 33 
Mutations in the Trypanosoma brucei aquaporin AQP2 are associated with resistance to 34 
pentamidine and melarsoprol. We show that TbAQP2 but not TbAQP3 was positively 35 
selected for increased pore size from a common ancestor aquaporin. We demonstrate that 36 
TbAQP2’s unique architecture permits pentamidine permeation through its central pore and 37 
show how specific mutations in highly conserved motifs affect drug permeation. Introduction 38 
of key TbAQP2 amino acids into TbAQP3 renders the latter permeable to pentamidine. 39 
Molecular dynamics demonstrates that permeation by dicationic pentamidine is energetically 40 
favourable in TbAQP2, driven by the membrane potential, although aquaporins are normally 41 
strictly impermeable for ionic species. We also identify the structural determinants that make 42 
pentamidine a permeant although most other diamidine drugs are excluded. Our results have 43 
wide-ranging implications for optimising antitrypanosomal drugs and averting cross-44 
resistance. Moreover, these new insights in aquaporin permeation may allow the 45 
pharmacological exploitation of other members of this ubiquitous gene family. 46 
 47 
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Introduction 51 
The Trypanosoma brucei-group species are protozoan parasites that cause severe and fatal 52 
infections in humans (sleeping sickness) and animals (nagana, surra, dourine) (Giordani et al, 53 
2016; Büscher et al, 2017). The treatment is dependent on the sub-species of trypanosome, on 54 
the host, and on the stage of the disease (Giordani et al, 2016; De Koning, 2020). Many anti-55 
protozoal drugs are inherently cytotoxic but derive their selectivity from preferential uptake 56 
by the pathogen rather than the host cell (Munday et al, 2015a; De Koning, 2020). 57 
Conversely, loss of the specific drug transporters is a main cause for drug resistance (Barrett 58 
et al, 2011; Baker et al, 2013; Munday et al, 2015a; De Koning, 2020). This is the case for 59 
almost all clinically used trypanocides, including diamidines such as pentamidine and 60 
diminazene (Carter et al, 1995; De Koning, 2001a; De Koning et al, 2004; Bridges et al, 61 
2007), melaminophenyl arsenicals such as melarsoprol and cymelarsan for cerebral stage 62 
human and animal trypanosomiasis, respectively (Carter & Fairlamb, 1993; Bridges et al, 63 
2007), and the fluorinated amino acid analogue eflornithine for human cerebral 64 
trypanosomiasis (Vincent et al, 2010). The study of transporters is thus important for anti-65 
protozoal drug discovery programmes as well as for the study of drug resistance (Lüscher et 66 
al, 2007; Munday et al, 2015a). 67 
 In Trypanosoma brucei, the phenomenon of melarsoprol-pentamidine cross-resistance 68 
(MPXR) was first described shortly after their introduction (Rollo & Williamson, 1951), and 69 
was linked to reduced uptake rather than shared intracellular target(s) (Frommel & Balber, 70 
1987). The first transporter to be implicated in MPXR was the aminopurine transporter 71 
TbAT1/P2 (Carter & Fairlamb, 1993; Mäser et al, 1999; Munday et al, 2015b) but two 72 
additional transport entities, named High Affinity Pentamidine Transporter (HAPT1) and 73 
Low Affinity Pentamidine Transporter (LAPT1), have been described (De Koning, 2001a; 74 
De Koning & Jarvis, 2001; Bridges et al, 2007). HAPT1 was identified as Aquaglyceroporin 75 
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2 (TbAQP2) via an RNAi library screen, and found to be the main determinant of MPXR 76 
(Baker et al, 2012, 2013; Munday et al, 2014). The apparent permissibility for high molecular 77 
weight substrates by TbAQP2 was attributed to the highly unusual selectivity filter of 78 
TbAQP2, which lacks the canonical aromatic/arginine (ar/R) and full NPA/NPA motifs, 79 
resulting in a much wider pore (Baker et al, 2012; Munday et al, 2014, 2015a). Importantly, 80 
the introduction of TbAQP2 into Leishmania promastigotes greatly sensitised these cells to 81 
pentamidine and melarsen oxide (Munday et al, 2014). Moreover, in several MPXR 82 
laboratory strains of T. brucei the AQP2 gene was either deleted or chimeric after cross-over 83 
with the adjacent TbAQP3 gene, which, unlike AQP2, contains the full, classical ar/R and 84 
NPA/NPA selectivity filter motifs and is unable to transport either pentamidine or 85 
melaminophenyl arsenicals (Munday et al, 2014). Similar chimeric genes and deletions were 86 
subsequently isolated from sleeping sickness patients unresponsive to melarsoprol treatment 87 
(Graf et al, 2013; Pyana Pati et al, 2014) and failed to confer pentamidine sensitivity when 88 
expressed in a tbaqp2-tbaqp3 null T. brucei cell line whereas wild-type TbAQP2 did 89 
(Munday et al, 2014; Graf et al, 2015). 90 
The model of drug uptake through a uniquely permissive aquaglyceroporin (Munday 91 
et al, 2015a) was challenged by a study arguing that instead of traversing the TbAQP2 pore, 92 
pentamidine merely binds to an aspartate residue (Asp265) near the extracellular end of the 93 
pore, above the selectivity filter, followed by endocytosis (Song et al, 2016). This alternative, 94 
‘porin-receptor’ hypothesis deserves careful consideration given that (i) it is an exceptional 95 
assertion that drug-like molecules with molecular weights grossly exceeding those of the 96 
natural substrates, can be taken up by an aquaglyceroporin and (ii) the fact that bloodstream 97 
form trypanosomes do have, in fact, a remarkably high rate of endocytosis (Field & 98 
Carrington, 2009; Zoltner et al, 2016). The question is also important because aquaporins are 99 
found in almost all cell types and the mechanism by which they convey therapeutic agents 100 
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and/or toxins into cells is of high pharmacological and toxicological interest. While TbAQP2 101 
is the first aquaporin described with the potential to transport drug-like molecules, this ability 102 
might not be unique, and the mechanism by which the transport occurs should be carefully 103 
investigated. 104 
We therefore conducted a mutational analysis was undertaken, swapping TbAQP2 105 
and TbAQP3 selectivity filter residues and altering pore width at its cytoplasmic end. This 106 
was complemented with a thorough structure-activity relationship study of the interactions 107 
between pentamidine and TbAQP2, using numerous chemical analogues for which inhibition 108 
constants were determined and interaction energy calculated. The pentamidine-TbAQP2 109 
interactions were further modelled by running a molecular dynamics simulation on a protein-110 
ligand complex, and in addition, we investigated a potential correlation between the T. brucei 111 
endocytosis rate and the rate of pentamidine uptake. Our results provide strong evidence for 112 
pentamidine permeating directly through the central pore of TbAQP2. Having identified the 113 
essential characteristics that allow the transport of large, flexible molecules through TbAQP2, 114 
this should now allow the evaluation of aquaporins in other species for similar adaptations.   115 
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Results 116 
 117 
12. Investigation of the structural determinants of AQP2 for pentamidine transport 118 
1.1. Positive selection for pore size 119 
In T. brucei, the AQP2 and AQP3 genes are arranged as a tandem pair on chromosome 10 120 
and have 74% amino acid identity. Whereas TbAQP2 clearly mediates pentamidine uptake, 121 
TbAQP3 does not (Baker et al, 2012; Munday et al, 2014), nor do various chimeric AQP2/3 122 
rearrangements that give rise to pentamidine resistance (Munday et al, 2014; Graf et al, 123 
2015). To investigate the origin of the AQP2 gene, a phylogenetic analysis of AQPs in 124 
African trypanosomes was performed. The number of aquaporin genes varies: there is a 125 
single aquaporin in T. vivax and T. congolense, two in T. suis and three in T. brucei and its 126 
derivatives and the most probable tree (Figure 1) is consistent with the evolutionary history of 127 
the four species (Hutchinson & Gibson, 2015), and indicates AQP1 as the ancestral AQP 128 
present in all trypanosome species. A duplication occurred in the common ancestor of T. 129 
suis and T. brucei after divergence from T. congolense and a further duplication, to form 130 
AQP2 and AQP3, in the ancestor of T. brucei after divergence from T. suis. Multiple 131 
alignment (Figure 1-figure supplement 1) shows that the classical NPA/NPA and ar/R AQP 132 
selectivity filter elements are present in all AQPs except T. brucei AQP2. The divergence of 133 
T. brucei AQP2 and 3 was investigated by calculating the non-synonymous/synonymous 134 
codon ratio (dN/dS) for different AQPs (Figure 1-figure supplement 2). For T. brucei aligned 135 
with T. suis AQP1, dN/dS is 0.21 and for AQP3, dN/dS is 0.30 indicating purifying selection. 136 
However, comparing T. brucei AQP2 with T. brucei AQP3, dN/dS is 2.0 indicating strong 137 
selection pressure for divergence on AQP2 towards an aquaporin with increased pore size. In 138 
order to verify any role of amino acids along the TbAQP2 pore in facilitating pentamidine 139 
sensitivity and/or uptake, we performed a mutational analysis. 140 
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 141 
1.2 Introduction of AQP3 residues into the AQP2 selectivity filter 142 
One highly conserved motif of aquaporins, believed to be essential for permeant selectivity, 143 
is NPA/NPA which is present in TbAQP3 but not in TbAQP2, where, uniquely, it is 144 
NS
131
A/NPS
263
 instead. We therefore constructed a TbAQP2 variant with the classical 145 
NPA/NPA motif (TbAQP2
S131P/S263A
) and expressed it in the aqp2/aqp3 null cell line (Baker 146 
et al, 2012; Munday et al, 2014). In this cell line, uptake of 30 nM [
3
H]-pentamidine was 147 
reduced to 4.40 ± 0.71% (n=4) of the rate in the control line expressing TbAQP2WT (P<0.05, 148 
Student’s unpaired t-test), as well as significantly different from the rate measured in parallel 149 
in the tbaqp2/tbaqp3 null cells (P<0.01) (Figure 2A). The remaining pentamidine uptake was 150 
sufficient to strongly sensitise the TbAQP2
S131P/S263A
 cells to pentamidine in a standard 151 
protocol of 48 h incubation with the drug followed by a further 24 h in the presence of the 152 
resazurin indicator dye (P<0.0001 vs tbaqp2/tbaqp3 null) but the EC50 was still significantly 153 
higher than the TbAQP2WT control (P<0.05) (Figure 2B). A similar effect was observed for 154 
the melaminophenyl arsenical drug cymelarsan, but there was no change in sensitivity to 155 
diminazene or the control drug phenylarsine oxide (PAO), which is believed to diffuse 156 
directly across the membrane (Fairlamb et al, 1992) (Figure 2B).  157 
 The mutant L258Y, which has the AQP3 Tyr-250 half of the highly conserved 158 
aromatic/arginine (ar/R) motif, responsible for pore restriction and proton exclusion (Wu et 159 
al, 2009), introduced into the TbAQP2 pore, yielded a drug transport phenotype similar to 160 
TbAQP2
S131P/S263A
. The [
3
H]-pentamidine transport rate was reduced to 6.6 ± 1.4% of 161 
TbAQP2WT (P<0.05) but remained above the rate in the tbaqp2/tbaqp3 null cells (P<0.01) 162 
(Figure 2A). Pentamidine and cymelarsan EC50 values were also significantly different from 163 
both the TbAQP2WT and the tbaqp2/tbaqp3 null controls (Figure 2C).  164 
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 The ar/R motif is part of the larger selectivity filter, usually WGYR, present in both 165 
TbAQP1 and TbAQP3 but uniquely consisting of I
110
VL
258
L
264
 in TbAQP2 (Baker et al, 166 
2013), all non-polar, open chained residues. Cell lines expressing mutations AQP2
I110W
 and 167 
AQP2
L264R
, either alone or in combination, displayed pentamidine transport rates, and 168 
pentamidine and cymelarsan EC50 values that were not significantly different from the 169 
tbaqp2/tbaqp3 null controls but highly significantly different from the TbAQP2WT drug-170 
sensitive controls, showing that their capacity for pentamidine and cymelarsan uptake had 171 
been reduced to zero (Figure 2A, D-F).  172 
We conclude that the unique TbAQP2 replacement of the NPA/NPA motif and all of 173 
the WGYR selectivity filter mutations are necessary for the observed pentamidine and 174 
melaminophenyl arsenical sensitivity observed in cells expressing wild-type TbAQP2. 175 
 176 
1.3 Introduction of TbAQP2 selectivity filter residues into the AQP3 pore enables 177 
pentamidine transport 178 
An interesting question was whether the introduction of (some of) the critical 179 
TbAQP2 residues in TbAQP3 might give the latter the capacity to take up pentamidine. We 180 
therefore constructed TbAQP3
W102I/R256L
 and TbAQP3
W102I/R256L/Y250L
 and tested whether 181 
tbaqp2/tbaqp3 null cells transfected with these mutant aquaporins were able to take up 25 nM 182 
[
3
H]-pentamidine in the presence of 1 mM adenosine (which blocks uptake via TbAT1/P2). 183 
Pentamidine uptake in the tested cell lines was very low compared to the same cells 184 
expressing TbAQP2WT (Figure 2G). However, by measuring [
3
H]-pentamidine uptake over 185 
30 min it was possible to reliably and reproducibly measure radiolabel accumulation in each 186 
cell line. This showed that while uptake in TbAQP3
W102I/R256L
 only trended slightly upwards 187 
(P>0.05), the mutant AQP3 with all three AQP2 WGYR residues (W102I, R256L and 188 
Y250L) accumulated significantly more [
3
H]-pentamidine than the tbaqp2/tbaqp3 null cells 189 
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(P<0.01) or the null cells expressing TbAQP3WT (P=0.011). This is further corroborated by 190 
comparing the pentamidine sensitivity profile of these cell lines: only TbAQP3
W102I/R256L/Y250L
 191 
conveyed significant sensitisation to tbaqp2/tbaqp3 null cells (P<0.0001; Figure 2H). Thus, 192 
TbAQP3 is converted into a pentamidine transporter by the insertion of the AQP2 WGYR 193 
residues, although this does not convey as high a rate of pentamidine uptake as TbAQP2. 194 
Similar experiments did not show any sensitisation to cymelarsan upon expression of 195 
TbAQP3 or mutants TbAQP3
W102I/R256L
 and TbAQP3
W102I/R256L/Y250L
, although the latter 196 
mutant actually showed a 50% higher EC50 concentration (P<0.001); EC50 values were 114 ± 197 
5%, 105 ± 8% and 159 ± 8% of the tbaqp2/tbaqp3 control, respectively (n≥7).  198 
 199 
1.4 Mutations of amino acids modelled to potentially bind pentamidine or melarsoprol 200 
dramatically reduce pentamidine transport 201 
Our previous attempts at modelling the binding of pentamidine and melarsoprol into 202 
the pore of TbAQP2 tentatively identified several residues that could be involved in this 203 
process (Munday et al, 2015a), from which we selected two residues, Ile190 and Trp192, at 204 
the extracellular end of the channel (position shown in Figure 7), to swap with the 205 
corresponding residues of TbAQP3, creating TbAQP2
I190T
 and TbAQP2
W192G
. Both residues 206 
were predicted to interact with the substrate(s) via main-chain carbonyl oxygen atoms, but the 207 
side chains could nonetheless affect the interactions.  208 
TbAQP2
I190T
 displayed dramatically reduced [
3
H]-pentamidine uptake, at 2.7 ± 0.7% 209 
(P<0.01, n=4) of the TbAQP2WT control, although significantly higher than the rate of the 210 
tbaqp2/tbaqp3 null negative control (P<0.05) (Figure 3A). The reduced rate was the result of 211 
a reduced Vmax of the high affinity [
3
H]-pentamidine uptake, rather than a change in Km; the 212 
LAPT1 Vmax and Km were unchanged in cells expressing TbAQP2
I190T
 or TbAQP2WT 213 
(Figure 3-figure supplement 1). TbAQP2
I190T
 still conferred some increased pentamidine 214 
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sensitivity in the standard resazurin test (P<0.0001), although highly significantly less 215 
sensitizing than TbAQP2WT (P<0.001); an intermediate sensitivity was also observed for 216 
cymelarsan (Fig. 3B). Substitution W192G also produced intermediate sensitivity to both 217 
drugs (Figure 3C) but the double substitution TbAQP2
I190T/W192G
 displayed no significant 218 
pentamidine uptake above tbaqp2/tbaqp3 null (Fig. 3A) and did not sensitise to pentamidine 219 
or cymelarsan (Figure 3D).  220 
 221 
1.5. The effect of large amino acids at the cytoplasmic end of the pore.  222 
To test whether restrictions at the cytoplasmic end of TbAQP2 would impact on pentamidine 223 
transport, we selected three leucine residues and exchanged each with tryptophan, creating 224 
L84W, L118W and L218W (positions indicated in Figure 7). Expressing each of the L-to-W 225 
mutants in tbaqp2/tbaqp3 null cells revealed significantly reduced pentamidine sensitivity 226 
compared to the same cells expressing TbAQP2WT (Figure 4A), while also exhibiting 227 
dramatically reduced rates of [
3
H]-pentamidine transport (Figure 4B). This effect was 228 
additive, with TbAQP2
L84W/L118W
 not significantly sensitising for pentamidine and displaying 229 
no detectable increase in [
3
H]-pentamidine transport relative to tbaqp2/tbaqp3 null cells 230 
(Figure 4A,B). None of these L-to-W mutants sensitised the cells to cymelarsan, diminazene 231 
or PAO, except that the L218W mutant sensitised slightly to diminazene (~2-fold, P<0.05; 232 
compared to 20-fold for pentamidine, P<0.0001) (Figure 4-figure supplement 1). When the 233 
same leucine residues were replaced with methionine instead of tryptophan, variants L84M 234 
and L218M were not or barely different from TbAQP2WT with respect to pentamidine 235 
sensitisation (Figure 4A) or transport (but highly significantly different from their respective 236 
tryptophan variants). For position 118 the Met replacement had similar effects as the Trp 237 
variant had, albeit with a significantly higher rate of pentamidine transport (1.88 ± 0.20 (n=6) 238 
versus 9.38 ± 0.63% (n=3) of TbAQP2WT, P<0.001; Figure 4A,B). The L84M and L218M 239 
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mutants also sensitised to cymelarsan (P<0.01) and, surprisingly, the L218 M mutants also 240 
sensitised somewhat to diminazene (~2-fold, P<0.05) (Figure 4-figure supplement 1).  241 
These results strongly argue that the introduction of large amino acids at the cytosolic 242 
end significantly blocks the transport of pentamidine, whereas the change to LeuMet 243 
mutants were more permissive for pentamidine, but not cymelarsan. In order to check 244 
whether these variants were still functional aquaglyceroporins, we used the observation of 245 
Jeacock et al, (2017) that T. brucei cells lacking all three AQPs are sensitised to the 246 
Trypanosome Alternative Oxidase inhibitor SHAM, as a result of cellular glycerol 247 
accumulation. By this measure, all of the position 84, 118 and 218 Trp and Met mutants were 248 
able to transport glycerol, as each displayed SHAM EC50 values significantly different from 249 
the tbaqp1-2-3 null cells (Figure 4C,D); several variants displayed an intermediate SHAM 250 
EC50, being also significantly different from TbAQP2WT, indicating some attenuation of 251 
glycerol efflux capacity for those mutants. Indeed, uptake of [
3
H]-glycerol closely mirrored 252 
the SHAM observations (Figure 4E).  253 
 254 
1.6. Overall correlation between [
3
H]-pentamidine transport rate and pentamidine EC50  255 
The results presented in Figures 2-4 consistently show that even TbAQP2 mutants that 256 
display a large reduction in [
3
H]-pentamidine uptake rate results can show intermediate 257 
pentamidine sensitivity phenotypes (EC50s), due to the nature of the standard drug sensitivity 258 
test employed, which involves a 48-h incubation with the drug prior to a further 24-h 259 
incubation with resazurin: even a much-reduced transport rate will be sufficient to 260 
accumulate significant amounts of intracellular pentamidine over 3 days. A plot of [
3
H]-261 
pentamidine transport rates versus pentamidine EC50, using the data for all 19 TbAQP2 and 262 
TbAQP3 mutants for which the transport rates were determined, shows that relatively small 263 
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changes in EC50 occur, even with up to approximately 95% reduction in transport rates; at 264 
>95% reduction large EC50 increases become apparent (Figure 4-figure supplement 2). 265 
 266 
2. Partially blocking endocytosis does not alter the rate of pentamidine transport and 267 
pentamidine does not trigger AQP2 endocytosis in bloodstream form T. brucei. 268 
The knockdown of the CRK12 kinase in T. brucei causes a highly reproducible defect in 269 
endocytosis that affects an estimated one third of cells 12 h after RNAi induction and is 270 
ultimately lethal (Monnerat et al, 2013). We utilized this system to investigate whether a link 271 
between endocytosis and pentamidine transport exists. At 12 h of CRK12 RNAi induction 272 
with tetracycline, CRK12 mRNA levels were reduced by 42% (P<0.001) relative to 273 
uninduced controls as determined by qRT-PCR (Figure 5A). Samples from the culture taken 274 
at this time point showed an increased abundance of cells with swelling characteristic of 275 
endocytosis defects, although this was hard to quantify as a minority of cells were affected, 276 
and to various degrees, as the 12 h time point was deliberately taken at as early a point as 277 
possible, so as not to affect cell viability (Figure 5-figure supplement 1) or cause excessive 278 
cellular pathology. We thus performed parallel uptake experiments with [
3
H]-pentamidine 279 
and [
3
H]-suramin, with suramin acting as positive control as it is known to enter T. brucei 280 
bloodstream forms through endocytosis after binding to surface protein ISG75 (Zoltner et al, 281 
2016, 2020). After 12 h of CRK12 RNAi induction, pentamidine uptake was not significantly 282 
less than in the T. brucei 2T1 parental cells, whereas uptake of [
3
H]-suramin was (P=0.019, 283 
n=5; Figure 5B, C). 284 
As this approach is necessarily limited to a partial inhibition of endocytosis in BSF T. 285 
brucei, it was also investigated whether pentamidine induces the internalisation and turnover 286 
of TbAQP2, as could be expected if the protein acts to internalise substrate by receptor-287 
mediated endocytosis. Cells pre-treated with the protein synthesis inhibitor cycloheximide 288 
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(100 µg/ml) were incubated in the presence or absence of 25 nM pentamidine and the 289 
abundance of 3×HA-tagged TbAQP2 was followed over a period of 6 h by Western blot 290 
(Figure 6, figure supplement 1). Quantification of the bands showed identical turnover rates 291 
with or without pentamidine present in the medium (Figure 6).  292 
 293 
3. The protonmotive force drives AQP2-mediated pentamidine uptake in bloodstream forms 294 
of T. brucei 295 
It has been reported that knock-down of the HA1–3 plasma membrane proton pumps of T. 296 
brucei (which are essential for maintaining the plasma membrane potential), confers 297 
pentamidine resistance (Alsford et al, 2012; Baker et al, 2013). Interestingly, this locus only 298 
conferred resistance to (dicationic) pentamidine, not to the (neutral) melaminophenyl 299 
arsenicals, unlike knockdown of the TbAQP2/TbAQP3 locus (Alsford et al, 2012). We have 300 
previously reported that the HAPT-mediated pentamidine uptake in T. brucei procyclics 301 
correlates strongly with the proton-motive force (PMF) (De Koning, 2001a). However, it is 302 
not clear whether this dependency indicates that pentamidine uptake is mediated by a proton 303 
symporter, as known for many T. brucei nutrient transporters (De Koning & Jarvis, 1997a,b, 304 
1998; De Koning et al, 1998), or reflects the energetics of uptake of cationic pentamidine 305 
being driven by the strong inside-negative membrane potential Vm. The absence of an effect 306 
of HA1–3 knockdown on sensitivity to the neutral melaminophenyl arsenicals strongly argues 307 
against a mechanism of proton symport for HAPT1/AQP2 but a (partial) dependency of 308 
HAPT1/AQP2-mediated uptake of dicationic pentamidine on PMF or Vm would be expected 309 
if the substrate traverses the channel, as opposed to binding a single Asp residue on the 310 
extracellular side of the protein, as suggested in the endocytosis model (Song et al, 2016). 311 
Here we show that the same ionophores that inhibit HAPT1-mediated pentamidine transport 312 
in procyclic cells, and inhibit hypoxanthine uptake in both bloodstream form (BSF) (De 313 
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Koning & Jarvis, 1997b) and procyclic (De Koning & Jarvis, 1997a) T. brucei, also dose-314 
dependently inhibit [
3
H]-pentamidine uptake in BSF (Figure 7A). This confirms that 315 
pentamidine needs the membrane potential for rapid uptake, as predicted by the dependence 316 
on the HA1–3 proton pumps. Using [
3
H]-suramin as an endocytosed substrate (Zoltner et al, 317 
2016), we found that 20 µM CCCP also inhibits endocytosis in T. brucei, by 32.6% 318 
(P=0.029; pre-incubation 3 min, plus suramin accumulation over 10 minutes) (Figure 7B). 319 
While that means that the ionophore experiments do not perfectly discriminate between 320 
endocytosis and trans-channel transport for di-cationic pentamidine, they do for neutral 321 
melaminophenyl arsenicals: the non-dependence of these neutral TbAQP2 substrates on the 322 
proton gradient (Alsford et al, 2012) indicates that, unlike suramin, they are not endocytosed.  323 
Although there is a good correlation between the proton-motive force and TbAQP2-324 
mediated pentamidine transport (Figure 7C), the effect of CCCP was stronger than expected, 325 
and stronger than previously observed for [
3
H]-hypoxanthine uptake in T. brucei bloodstream 326 
forms (De Koning & Jarvis 1997b) and we thus investigated whether CCCP might have a 327 
direct effect on TbAQP2. Indeed, CCCP inhibited uptake of (neutral) [
3
H]-glycerol in 328 
tbaqp1-2-3 null cells expressing TbAQP2-WT, with an IC50 of 20.7 ± 2.6 µM (n=3) and 329 
inhibited [
3
H]-pentamidine uptake in the same cells with a similar IC50 (Figure 7D,E), 330 
showing CCCP to inhibit TbAQP2 directly, irrespective of effects on the membrane potential. 331 
Figure 7D also shows that pentamidine, used as a control, inhibits [
3
H]-glycerol uptake with 332 
an EC50 value (Mean of 27.5 nM, n=2) similar to the EC50 of pentamidine inhibiting uptake 333 
of [
3
H]-pentamidine. 334 
 335 
4. Molecular dynamics modelling of pentamidine interactions with TbAQP2 336 
To further investigate pentamidine binding and permeation in TbAQP2, we used the 337 
coordinates of the TbAQP2-pentamidine complex that was modelled in our previous study 338 
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(Munday et al, 2015a). The stability of the protein model was first confirmed by unbiased 339 
atomistic molecular dynamics simulations (Figure 8-figure supplement 1). We then 340 
conducted force-probe simulations, in which a moving spring potential was used to enforce 341 
unbinding of pentamidine from its docked binding position and subsequently reconstructed 342 
the free-energy profile of pentamidine association-dissociation along the pore axis by 343 
employing Jarzynski’s equality (Park et al, 2003). 344 
Figure 8A shows that the docked position of pentamidine correctly identified its 345 
minimum free-energy binding site inside the TbAQP2 pore. Pentamidine adopts an extended 346 
state inside the TbAQP2 pore, adapting its molecular shape to the narrow permeation 347 
channel; pentamidine binding poses display inter-amidine lengths in the range 16.5 – 17 Å. 348 
Importantly, our steered simulations reveal that pentamidine can exit the channel in either 349 
direction, and that unbinding on the route towards the cytoplasm occurs on a free-energy 350 
surface roughly symmetric to that towards the extracellular side. Apart from overcoming the 351 
strongly attractive binding interaction in the centre, there are no major further free-energy 352 
barriers in either direction. The computed free-energy profile of pentamidine binding to the 353 
TbAQP2 structural model slightly overestimates its experimentally recorded binding affinity. 354 
However, the pentamidine conformation binding the narrow pore may not be the lowest-355 
energy internal conformation of the small molecule, a factor that may be underrepresented in 356 
the profile as simulations were started from the protein-bound state. A further source of 357 
uncertainty stems from the protein model, which is expected to be somewhat less accurate 358 
than a crystal structure. 359 
Due to the dicationic character of pentamidine, the free-energy profile of the molecule 360 
within TbAQP2 strongly depends on the membrane voltage. The voltage drop of -125 mV 361 
across the cytoplasmic membrane of T. b. brucei (De Koning & Jarvis, 1997b), with a 362 
negative potential inside the cell, results in an overall inward attraction of ~22 kJ/mol (Figure 363 
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8A, arrow), i.e. exit from TbAQP2 into the cytoplasm is substantially more favourable for 364 
pentamidine than towards the extracellular side. Taken together, the free-energy profile under 365 
membrane voltage explains the strong coupling between pentamidine uptake and Vm 366 
observed in the experiments. The high affinity of the binding interaction leads to slow off-367 
rates and a relatively low Vmax (0.0044 ± 0.0004 pmol(10
7
 cells)
-1
s
-1
) (De Koning, 2001a).  368 
 We further investigated the bound positions of pentamidine and melarsoprol in AQP2 369 
by docking, in order to rationalise the differential behaviour of pentamidine and 370 
melaminophenyl arsenicals observed in the studied AQP2 mutants. The binding modes in the 371 
central pore of AQP2 obtained by docking are shown in Figure 8B. They reveal that both 372 
drugs are likely to bind to the same general region within the central pore in spite of their 373 
different sizes and charge states.  374 
 Figure 1 shows that replacing the AQP2 NSA/NPS motif in the selectivity filter of the 375 
pore with the consensus NPA/NPA motif of other aquaporins still allows pentamidine to 376 
permeate, although at substantially reduced rate, with an EC50 at >50-fold lower than the 377 
aqp2/aqp3 null control, while cymelarsan is almost completely blocked (EC50 ~60% of 378 
control). Similar observations are made for the L258Y mutant (Figure 1B,C). In contrast, the 379 
single mutant L264R did not allow either cymelarsan or pentamidine permeation (Figure  1A, 380 
E) and the double mutant I110W/L264R actually enabled a level of cymelarsan (but not 381 
pentamidine) permeation (Figure 1F). These findings can be rationalised by the differing 382 
structural features, interaction patterns, and charge of the two compounds (Figure 6B). The 383 
leucine to arginine substitution introduces a further positive charge into the central pore of the 384 
aquaporin, which repels the dicationic pentamidine molecule and is therefore likely to 385 
decrease its affinity to this variant, whereas the neutral arsenical compound is much less 386 
affected by the addition of positive charge into the pore.  387 
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Conversely, the shorter arsenical agent is more affected by introducing the NPA/NPA 388 
motif since its terminal polar function intensely interacts with the NSA/NPS motif, whereas 389 
the major interactions of pentamidine are seen outside this motif. In the case of the L258Y 390 
mutant, the difference can be attributed to the extended flexible linker region in the centre of 391 
pentamidine, which is likely to enable it to bend around the added bulky side chain in the 392 
mutant, while cymelarsan lacks this level of flexibility in its centre.  393 
Finally, the single and double mutations I190T and W192G have broadly similar 394 
effects on pentamidine and cymelarsan permeation across AQP2 (Figure 2) as both positions 395 
at the entrance to the pore exhibit similar interaction patterns to both pentamidine and the 396 
arsenical agent. 397 
 398 
5. SAR of the pentamidine-AQP2 interaction 399 
In order to study substrate binding and selectivity by the T. b. brucei High Affinity 400 
Pentamidine Transporter (HAPT1/TbAQP2), competition assays were performed with a 401 
series of pentamidine analogues and other potential inhibitors, in the presence of 1 mM 402 
unlabelled adenosine to block diamidine uptake by the TbAT1 aminopurine transporter (De 403 
Koning, 2001a; Bridges et al, 2007). High specific activity [
3
H]-pentamidine was used at 30 404 
nM, below the Km value (De Koning, 2001a). Uptake was linear for at least 3 min (De 405 
Koning, 2001a)
 
and we utilized 60 s incubations for the determination of inhibition constants 406 
(Ki). At 30 nM [
3
H]-pentamidine there is virtually no uptake through LAPT1 (Bridges et al, 407 
2007) (Km value ~1000-fold higher than HAPT1) (De Koning, 2001a). The full dataset of 71 408 
compounds is presented in Supplementary File 1, featuring Kis spanning 5 log units.  409 
 410 
5.1. The linker length and composition is a strong determinant for high affinity binding of 411 
pentamidine 412 
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We determined the Ki values for analogues with a 2–8 methylene unit linker (Figure 9A, 413 
Table 1). Pentamidine analogues featuring 5-7 units displayed submicromolar binding 414 
affinities (5 > 6 > 7), while fewer (3-4) or more (8) only conveyed low micromolar binding 415 
affinity, equivalent to a decrease in Gibbs free energy of binding (ΔG0) from 10.2 to 13.0 416 
kJ/mol (Table 1). Energy minimalization using Gaussian16 yielded an elongated 417 
conformation for pentamidine, with an inter-amidine length of 17.8 Å (Figure 7B). 418 
Replacement of the ether oxygens with S or NH, analogues RT-48 and RT-50, respectively 419 
(Table 1) resulted in δ(ΔG0) of 10.0 and 12.9 kJ/mol, respectively, indicating that the ether 420 
oxygens potentially act as H-bond acceptors: the NH group serves only as an H-bond donor, 421 
as its lone pair is conjugated with the aromatic system, and the sulphur mimics an aromatic 422 
NH (Beno et al, 2015). The sulfone analogue (RT-49), which introduces a dihedral angle of 423 
180° between the benzamidine and the linker (Brameld et al, 2008), displayed no binding 424 
affinity. We propose that a near-planar conformation of the Phe-O-CH2 segment is required 425 
for efficient engagement of the binding site. This is supported by examining the binding 426 
affinities found for the analogous benzofuramidine series (e.g. RT-14, Figure 9B), which has 427 
a conformationally predefined ether-methylene bond orientation. Replacement of the middle 428 
methylene unit of pentamidine with an isosteric oxygen (ethylene glycol derivative DB1699, 429 
Table 1) results in a less flexible linker and a remarkable drop in binding affinity (δ(ΔG0) = 430 
15.3 kJ/mol). 431 
 432 
5.2. Two amidine groups are required for high affinity binding  433 
Matched-molecular pair analysis of non-symmetric analogues identified that both amidines 434 
contribute to high affinity binding (compare pairs pentamidine/RT-36 and 435 
pentamidine/CHI/1/72/1; Table 1). Removal of an H-bond donor (as in CHI/1/72/1) leads to a 436 
loss in ΔG0 >10 kJ/mol. The aniline derivative RT-36 can still act as an H-bond donor, albeit 437 
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with significantly reduced basicity (and thus H-bond acceptor propensity), and accordingly 438 
displayed intermediate affinity (δ(ΔG0) = 6.2 kJ/mol). Interestingly, the removal of one 439 
amidine (compare butamidine and CHI/1/69/1) did not produce a significant effect on the 440 
binding affinity (Ki = 3.87 µM and Ki = 2.33 µM, respectively), indicating that the low 441 
affinity of butamidine (compare 36 nM for pentamidine) is due to an inability to attain a 442 
productive interaction with the second amidine. Capping of the amidine group, resulting in 443 
imidazoline analogue RT-32, or methylation (analogue RT-30) reduced binding to HAPT1, 444 
probably due to increased steric crowding at the interaction site, impairing H-bonding. 445 
Reducing pentamidine to just 4-hydroxybenzamidine removed essentially all affinity (Ki = 446 
2.9 mM; δ(ΔG0) = 28.1 kJ/mol), and the replacement of one amidine with a carboxylic group 447 
(compare propamidine, RT-38) was highly deleterious for engagement with the binding site. 448 
Finally, the orientation of the amidine group is crucial as shown by a meta to para change on 449 
the phenyl ring (meta-pentamidine, Table 1). We conclude that for high affinity both amidine 450 
groups must be able to interact unimpeded with the transporter, and in the linear (para) 451 
conformation. 452 
 453 
5.3. Fully conjugated linking units 454 
Stilbamidine and the short-linker analogues FR39 and CRMI8 (Ríos Martínez et al, 455 
2015) displayed low binding affinity (Table 1). Diminazene also displayed similar low 456 
affinity (Ki = 63 µM), and [
3
H]-diminazene uptake can only just be detected in procyclic T. b. 457 
brucei, i.e. in the absence of the TbAT1/P2 transporter (Teka et al, 2011), potentially 458 
indicating a minimal uptake via HAPT1. Stilbamidine and diminazene feature a similar inter-459 
amidine distance, much shorter than pentamidine (12.35 and 12.25 Å, respectively). DB75 460 
(furamidine) likewise displayed low affinity (Table 2) and is only internalised by TbAT1/P2 461 
(Ward et al, 2011). The 2,5-furan linker imposes a fixed, inflexible angle of 136º on the 462 
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benzamidine moieties and the phenyl rings will adopt a planar orientation with respect to the 463 
furan plane. This appears to allow only one benzamidine end to interact with the transporter, 464 
as (unlike the flexible linker of aliphatic diamidines, vide supra) the replacement of one 465 
amidine group actually increases the binding affinity, presumably by allowing an improved 466 
bonding orientation of the remaining amidine. Thus, DB607 (methoxy for amidine) and 467 
DB960 (N-methyl benzimidazole for benzamidine) display a somewhat higher affinity than 468 
DB75, although the fixed angle was unchanged. Introduction of a pyridine-N in the ortho-469 
position with respect to the amidine functionality (DB994), dramatically reduces the pKa of 470 
the amidine moiety (Wang et al, 2010), resulting in a complete loss of binding affinity (Ki = 471 
167 ± 20 µM), while this was not observed for the corresponding meta-pyridine derivative 472 
(DB829). The unfavourable furan bond angle is further demonstrated by the distally 473 
elongated analogues DB1061 and DB1062 that approximate the inter-amidine distance of 474 
pentamidine but showed no improvement in binding affinity (Table 2). Replacement of furan 475 
with thiazole (ER1004) or methylpyrrole (DB320), which feature a similar bond angle, also 476 
revealed comparable binding affinities. In contrast, a 2,5-substituted thiophene (DB686 and 477 
DB1063) or 2,5-substituted selenophene (DB1213) as a bio-isosteric replacement for the 478 
furan linker resulted in significantly higher binding affinities when compared to their 479 
matched pair analogue (DB1063/DB1061 and DB1213/DB75), which we attribute to a larger 480 
benzamidine-benzamidine angle. This is corroborated by the much weaker binding of the 2,4-481 
thiophene derivative DB1077. A terminal amidine cap (imidazoline) reduced affinity as it did 482 
for pentamidine (compare DB1061/DB1062 and DB1063/DB1064 (Table 2)). A difuran 483 
spacer (DB914) resulted in a high affinity binder (Ki = 0.073 µM) because the two furans 484 
orient themselves in a trans conformation, resulting in a near-linear molecule.  485 
 486 
5.4. Modifications to the phenyl rings of pentamidine 487 
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Substituents in the ortho-position (relative to the alkyloxy substituent) of pentamidine were 488 
poorly tolerated, including chloride or iodide (RT-43, iodopentamidine; Table 1); the amide 489 
analogue displayed no affinity at all (RT-46). Such substituents will cause an out-of-plane 490 
conformation of the alkoxy-group to avoid clashing with the ortho-substituent; high-affinity 491 
pentamidine binding appears to require a coplanar arrangement of the first methylene bound 492 
to the oxygen. Similarly, the introduction of an ortho-pyridine N (RT-52) led to a δ(ΔG0) of 493 
13.7 kJ/mol. This derivative exhibits a conformational bias towards an anti-orientation of the 494 
ether oxygen and pyridine nitrogen (Figure 9C) (Chein & Corey, 2010). The regio-isomeric 495 
meta-pyridine (RT-53) was completely inactive, reflecting the need for a positively charged 496 
amidine, as this analogue has a significantly reduced pKa (Wang et al, 2010) (see furan-497 
spaced analogue DB994, supra).  498 
 499 
5.5. Non-diamidine trypanocides 500 
The important veterinary trypanocide isometamidium, a hybrid of the phenanthridine 501 
ethidium and the diamidine diminazene, inhibited HAPT1-mediated [
3
H]-pentamidine uptake 502 
with a Ki of only 3.5 µM (Supplementary File 1), most probably through an interaction with 503 
its benzamidine moiety, as ethidium displayed virtually no affinity (Ki = 97 µM). However, 504 
we found no evidence that HAPT1/AQP2 is able to transport the bulky isometamidium 505 
molecule. For instance, the 2T1, tbaqp2 null, TbAQP2 expressed in tbaqp2 null, and the 506 
tbaqp2/tbaqp3 null strains displayed statistically identical EC50 values for isometamidium 507 
(112 ± 12 nM, 103 ± 14 nM, 98 ± 24 nM and 95 ± 12 nM, respectively; P>0.05, Student’s 508 
unpaired t-test), and the EC50 values for ethidium were also identical for each of these strains 509 
(1.32 ± 0.07 µM, 1.39 ± 0.08 µM, 1.35 ± 0.11 µM and 1.38 ± 0.14 µM, respectively). It is 510 
thus likely that isometamidium acts as an extracellular inhibitor rather than a substrate for 511 
HAPT/AQP2, as it does for the TbAT1/P2 transporter (De Koning, 2001b). The nitro-512 
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heterocyclic trypanocide megazol (Carvalho et al, 2014), curcumin and its trypanocidal 513 
analogue AS-HK14 (Alkhaldi et al, 2015) failed to inhibit HAPT1. Two trypanocidal bis-514 
phosphonium compounds, CD38 (Taladriz et al, 2012) and AHI43 (Alkhaldi et al, 2016) did 515 
inhibit pentamidine uptake (Ki 5-10 µM), whereas two related compounds, CDIV31 and 516 
AHI15 (Taladriz et al, 2012), did not. Phloretin, which inhibits human AQP9 and AQP3 517 
(Geng et al, 2017),
47
 displayed a Ki of 1.76 µM for HAPT1/TbAQP2. 518 
 519 
5.6. Are all the HAPT1/AQP2 inhibitors transported? 520 
In an uptake-by-endocytosis model some correlation between TbAQP2 binding energy and 521 
TbAQP2-mediated uptake rates for each analogue would be expected, although in many 522 
instances of receptor-mediated endocytosis factors such as gating and the induction of 523 
conformational changes in the carrier might complicate such a correlation. Nevertheless, if 524 
we could observe a significant correlation of these parameters it would strengthen the 525 
argument for the endocytosis model. We were unable to ascertain the existence of such a 526 
correlation directly, for lack of radiolabelled substrates other than pentamidine and 527 
diminazene and thus used the Resistance Factor (RF; EC50(aqp2/3 null)/EC50(TbAQP2-WT)) 528 
as a proxy: clearly, a compound with a significant RF is internalized by TbAQP2. We 529 
observed a poor correlation between HAPT1 binding affinity and the level of resistance in the 530 
tbaqp2/tbaqp3 null strain (r
2
=0.039, Figure 9-figure supplement 1; n=30), with many 531 
inhibitors, even those with high affinity, not displaying any significant resistance in the null 532 
line. This indicates that many of these compounds inhibit HAPT1/TbAQP2 but are not 533 
transported by it. This fails to support a model in which pentamidine binds and is then 534 
internalized by endocytosis: the inhibitors do not show resistance in the tbaqp2/tbaqp3 null 535 
line, whereas substrates do. The lack of any correlation would be especially problematic for a 536 
model of ‘passive’ pentamidine endocytosis, where the drug merely piggy-backs on TbAQP2 537 
 24 
as it is internalised in its regular turnover schedule (t1/2 >4 h (Quintana et al. 2020)), without 538 
inducing any conformation changes in the receptor protein. The caveat inherent to using the 539 
RF instead of rate of transport is that it cannot be excluded that some of the test compounds 540 
are AQP2 substrates yet predominantly taken up by transporters other than TbAQP2, and 541 
hence show a low RF. 542 
 543 
5.7. SAR summary 544 
Figure 9D summarises the structure-activity relationship of pentamidine interactions with 545 
HAPT1/TbAQP2. No modification in any part of pentamidine improved affinity for 546 
TbAQP2, but virtually every modification resulted in a significant loss of binding activity (a 547 
similar analysis with melaminophenyl arsenicals was impossible for lack of the required 548 
organo-arsenicals). The results clearly demonstrate that at least both amidine groups and one 549 
or both ether oxygens are involved in interactions with AQP2, the sum of which adds up to 550 
the unusually high binding energy for this substrate-transporter pair (ΔG0 = -42.6 kJ/mol). 551 
These results are fully compatible with pentamidine binding in an elongated orientation, and 552 
are in complete agreement with the modelling and molecular dynamics, and the mutational 553 
analysis presented above, strengthening those conclusions using a completely different 554 
approach. 555 
  556 
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Discussion and conclusion 557 
 558 
There is overwhelming consensus that expression of TbAQP2 is associated with the 559 
extraordinary sensitivity of T. brucei to pentamidine and melaminophenyl arsenicals, and that 560 
mutations and deletions in this locus cause resistance (Baker et al, 2012, 2013; Graf et al, 561 
2013, 2015, 2016; Pyana Pati et al, 2014; Munday et al, 2014, 2015a; Unciti-Broceta et al, 562 
2015).
 
What has remained unclear, however, is the mechanism underpinning these 563 
phenomena – there are currently no documented other examples of aquaporins transporting 564 
such large molecules. Yet, considering how ubiquitous aquaporins are to almost all cell types, 565 
this question is of wide pharmacological importance: if large cationic and neutral drugs 566 
(pentamidine and melarsoprol, respectively) can be taken up via an aquaglyceroporin of T. 567 
brucei, what other pharmacological or toxicological roles may these channels be capable of in 568 
other cell types? This manuscript clearly shows that changes in the TbAQP2 WGYR and 569 
NPA/NPA motifs, which collectively enlarge the pore and remove the cation filter, allow the 570 
passage of these drugs into the cell, and thereby underpin the very high sensitivity of the 571 
parasite to these drugs. 572 
 TbAQP2 has evolved, apparently by positive selection given the high dN/dS ratio, to 573 
remove all main constriction points, including the aromatic amino acids and the cationic 574 
arginine of the ar/R selectivity filter, and the NPA/NPA motif, resulting in an 575 
unprecedentedly enlarged pore size (Baker et al, 2012; Munday et al, 2015). Whereas the 576 
advantage of this to T. b. brucei is yet unknown, the adaptation is stable within the brucei 577 
group of trypanosomes, and found in T. b. rhodesiense (Munday et al, 2014; Graf et al, 578 
2016), T. b. gambiense (Graf et al, 2013, 2015; Munday et al, 2014; Pyana Pati et al, 2014), 579 
T. equiperdum and T. evansi (Philippe Büscher and Nick Van Reet, unpublished). As such, it 580 
is not inappropriate to speculate that the wider pore of TbAQP2 (i) allows the passage of 581 
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something not transported by TbAQP1 and TbAQP3; (ii) that this confers an a yet unknown 582 
advantage to the cell; and (iii) that uptake of pentamidine is a by-product of this adaptation.  583 
 It is difficult to reconcile the literature on pentamidine transport/resistance with 584 
uptake via endocytosis. For instance, the rate of endocytosis in bloodstream trypanosomes is 585 
much higher than in the procyclic lifecycle forms (Langreth & Balber, 1975; Zoltner et al, 586 
2016), yet the rate of HAPT-mediated [
3
H]-pentamidine uptake in procyclics is ~10-fold 587 
higher than in bloodstream forms (De Koning, 2001a; Teka et al, 2011), despite the level of 588 
TbAQP2 expression being similar in both cases (Siegel et al, 2010; Jensen et al, 2014). 589 
Moreover, in procyclic cells TbAQP2 is spread out over the cell surface (Baker et al, 2012) 590 
but endocytosis happens exclusively in the flagellar pocket (Field & Carrington, 2009) 591 
(which is 3-fold smaller in procyclic than in bloodstream forms (Demmel et al, 2014)), as the 592 
pellicular microtubule networks below the plasma membrane prevent endocytosis (Zoltner et 593 
al, 2016). Thus, TbAQP2-mediated pentamidine uptake should be all but impossible in 594 
procyclic T. brucei, if dependent on endocytosis. Similarly, the expression of TbAQP2 in 595 
Leishmania mexicana promastigotes produced a rate of [
3
H]-pentamidine uptake more than 596 
10-fold higher than observed in T. brucei BSF (Munday et al, 2014), despite these cells also 597 
having a low endocytosis rate (Langreth & Balber, 1975). The Km and inhibitor profile of the 598 
TbAQP2-mediated pentamidine transport in these promastigotes was indistinguishable from 599 
HAPT in procyclic or bloodstream form T. brucei (De Koning, 2001a).  600 
The experimental Vmax for HAPT-mediated pentamidine uptake in T. brucei BSF and 601 
procyclics (De Koning, , 2001) can be expressed as 9.5×10
5
 and 8.5×10
6
 molecules/cell/h, 602 
respectively; given a 1:1 stoichiometry for AQP2:pentamidine the endocytosis model would 603 
require the internalisation and recycling of as many units of TbAQP2 and this seems unlikely, 604 
especially in procyclic cells, as even in BSF the half-life time for TbAQP2 turnover is >4 h 605 
(Quintana et al, 2020) and procyclic cells have a lower endocytosis rate and cannot easily 606 
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internalise the aquaporins spread over the cell surface, as discussed above. Given the 607 
observed rate of uptake and turnover rate, this would require the presence of ~4×10
6
 TbAQP2 608 
units per BSF cell in the flagellar pocket. These observations are all inconsistent with the 609 
contention that pentamidine uptake by trypanosomes is principally dependent on endocytosis. 610 
Although it is likely that AQP2-bound pentamidine is internalised as part of the natural 611 
turnover rate of the protein, this is not likely to contribute very significantly to the overall rate 612 
of uptake of this drug. 613 
Furthermore, the Gibbs free energy of -42 kJ/mol for the pentamidine/AQP2 614 
interaction (De Koning, 2001a; Zoltner et al, 2016) is highly unlikely to be the result of the 615 
one interaction between one terminal amidine and Asp265 as required in the endocytosis 616 
model (Song et al, 2016). For the TbAT1 transporter, a double H-bond interaction of Asp140 617 
with the N1(H)/C(6)NH2 motif of adenosine or with one amidine of pentamidine (Munday et 618 
al, 2015b) is estimated to contribute only ~16 kJ/mol to the total ΔG0 of -34.5 kJ/mol for 619 
adenosine (-36.7 kJ/mol, pentamidine) (De Koning & Jarvis, 1999). The endocytosis model 620 
also does not address the internalisation of melaminophenyl arsenicals, which presumably 621 
would equally need access to Asp265, or address why most diamidines including furamidines 622 
and diminazene aceturate are at best extremely poor substrates for TbAQP2 (Teka et al, 623 
2011; Ward et al, 2011). 624 
Here we systematically mapped the interactions between the aquaporin and 625 
pentamidine (ΔG0 for 71 compounds), yielding a completely consistent SAR with multiple 626 
substrate-transporter interactions, summarised in Figure 9D. The evidence strongly supports 627 
the notion that pentamidine engages TbAQP2 with both benzamidine groups and most 628 
probably with at least one of the linker oxygens, and that its flexibility and small width are 629 
both required to optimally interact with the protein. This is completely corroborated by 630 
molecular dynamics modelling, which shows minimal energy to be associated with a near-631 
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elongated pentamidine centrally in the TbAQP2 pore, without major energy barriers to 632 
exiting in either direction, but driven to the cytoplasmic side by the membrane potential. This 633 
contrasts with the contention (Song et al, 2016) that pentamidine could not be a permeant for 634 
TbAQP2 because it did not transport some small cations and that this proves that the larger 635 
pentamidine cannot be a substrate either. There is scant rationale for that assertion: out of 636 
many possible examples: there are 5 orders of magnitude difference in affinity for 637 
pentamidine and para-hydroxybenzamidine (35 nM vs 2.9 mM; Supplementary File 1); 638 
adenine is not a substrate for the T. brucei P1 adenosine transporter (De Koning & Jarvis, 639 
1999), the SLC1A4 and SLC1A5 neutral amino acid transporters transport Ala, Ser, Cys and 640 
Thr but not Gly (Kania et al, 2013), Na
+
 is not a permeant of K
+
 channels (Zhorov & 641 
Tikhonov, 2013) and some NAT family transporters from bacterial, plant and fungal species 642 
display much higher affinity for xanthine and uric acid but not for hypoxanthine (Gournas et 643 
al, 2008). 644 
 The endocytosis model identifies only two key residues for pentamidine access 645 
(Leu264) and binding (Asp265) in TbAQP2 (Song et al, 2016). Yet, multiple clinical isolates 646 
and laboratory strains contain chimeric AQP2/3 genes associated with resistance and/or non-647 
cure that have retained those residues and should thus allow binding and internalisation of 648 
pentamidine (Graf et al, 2013; Pyana Pati, 2014; Unciti Broceta et al, 2015; Munday et al, 649 
2014). Although we find that introduction of the AQP3 Arg residue in position 264 650 
(TbAQP2
L264R
) disables pentamidine transport, we would argue that this is because the 651 
positively charged arginine, in the middle of the pore, is blocking the traversing of all cations 652 
through the pore, as is its common function in aquaporins (Beitz et al, 2006; Wu et al, 2009). 653 
Indeed, the W(G)YR filter residues appear to be key determinants for pentamidine transport 654 
by AQPs and the introduction of all three TbAQP2 residues into TbAQP3 655 
(AQP3
W102I/R256L/Y250L
) was required to create an AQP3 that at least mildly sensitised to 656 
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pentamidine, and facilitated a detectable level of pentamidine uptake. Conversely, any one of 657 
the mutations I110W, L258Y or L264R was sufficient to all but abolish pentamidine 658 
transport by TbAQP2. Similarly, the conserved NPA/NPA motif, and particularly the Asp 659 
residues, present in TbAQP3 but NSA/NPS in TbAQP2, is also associated with blocking the 660 
passage of cations (Wree et al, 2011).
 
The unique serine residues in this TbAQP2 motif, 661 
halfway down the pore, might be able to make hydrogen bonds with pentamidine. Reinstating 662 
the NPA/NPA motif resulted in a TbAQP2 variant with a 93.5% reduced rate of [
3
H]-663 
pentamidine transport. 664 
 Tryptophan residues were introduced towards the cytoplasmic end of the TbAQP2 665 
pore (L84W, L118W, L218W) to test the hypothesis that introducing bulky amino acids in 666 
that position would block the passage of pentamidine. Each of these mutants was associated 667 
with reduced sensitivity to pentamidine and cymelarsan and a >90% reduction in [
3
H]-668 
pentamidine uptake. This effect was size-dependent as the pentamidine transport rate of 669 
L84M and L218M was statistically identical to that of control TbAQP2 cells, and L118M 670 
also displayed a higher transport rate than L118W (P<0.0001). These mutant AQPs were still 671 
functional aquaglyceroporins as their expression in tbaqp1-2-3 null cells made those cells less 672 
sensitive to the TAO inhibitor SHAM, and increased glycerol uptake. 
 
673 
Independence from endocytosis was investigated by employing the tetracycline-674 
inducible CRK12 RNAi cell line previously described to give a highly reproducible and 675 
progressive endocytosis defect in T. brucei (Monnerat et al, 2013), with the aim to distinguish 676 
between uptake via endocytosis and transporters, as current evidence suggests that in T. 677 
brucei all endocytosis, taking place exclusively in the flagellar pocket, is clathrin-dependent 678 
and AP-2 independent (Morgan et al, 2002; Allen et al, 2003). This means that the 679 
endocytotic mechanisms of TbAQP2 and suramin receptor ISG75, which are both directed to 680 
the lysosome after ubiquitylation (Quintana et al, 2020; Zoltner et al, 2015), are likely to be 681 
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similar enough for a direct comparison. Twelve hours after CRK12 RNAi induction 682 
pentamidine transport was not significantly reduced although uptake of [
3
H]-suramin, which 683 
is accumulated by endocytosis through the T. brucei flagellar pocket (Zoltner et al, 2016), 684 
was reduced by 33% (P=0.0027), indicating successful timing of the experiment to the early 685 
stage of endocytosis slow-down. We also show that pentamidine, at approximately its half-686 
maximal occupancy concentration, did not influence the half-life time of TbAQP2 turnover, 687 
as is often the case in receptor-mediated endocytosis. Nor should TbAQP2, which exists as a 688 
rigid tetramer of tetramers in T. brucei bloodstream forms (Quintana et al, 2020), be able to 689 
undergo the type of conformational change necessary to signal receptor occupancy and 690 
internalisation as observed in well-documented examples of ligand-triggered internalisation 691 
of transporters (e.g. Gournas et al, 2010, 2017; Ghaddar et al, 2014; Keener and Babst, 692 
2013). Thus, the combined evidence, taken together, strongly suggests that pentamidine is not 693 
taken up by endocytosis, not induce endocytosis of TbAQP2. 694 
Although several ionophores, including CCCP, nigericin and gramicidin strongly 695 
inhibited pentamidine uptake, similar to what has been previously reported for transport 696 
processes in T. brucei that are linked to the protonmotive force (De Koning & Jarvis, 697 
1997a,b, 1998; De Koning et al, 1998), this is probably due to the inside-negative membrane 698 
potential of -125 mV (De Koning & Jarvis, 1997b) attracting the dicationic pentamidine. This 699 
is consistent with the prediction of the molecular dynamics modelling, and the reported role 700 
of the HA1–3 proton pumps in pentamidine but not melarsoprol resistance (Alsford et al, 701 
2012; Baker et al, 2013). Although CCCP does inhibit pentamidine through direct, 702 
competitive inhibition of TbAQP2 as well, this only starts to have a measurable impact above 703 
~5 µM (IC50 of 20.7 µM), whereas its effects after preincubation, i.e. the combination of 704 
competitive inhibition and reducing the protonmotive force, shows ~63% inhibition of 705 
pentamidine transport at 1 µM and ~90% inhibition at 5 µM, showing that the more 706 
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important effect of CCCP is via reduction of the PMF. This is consistent with the conclusion 707 
from the molecular dynamics analysis that inward pentamidine flux is dependent on the 708 
inside-negative membrane potential. 709 
Altogether, we conclude that the primary entry of the sleeping sickness drugs 710 
pentamidine and melarsoprol into T. brucei spp. is through the unusually large pore of 711 
TbAQP2, rendering the parasite extraordinarily sensitive to the drugs (compare Leishmania 712 
mexicana (Munday et al, 2014)). This is the first report providing detailed mechanistic 713 
evidence of the uptake of organic drugs (of MW 340 and 398, respectively) by an aquaporin. 714 
We show that this porin has evolved through positive selection and identify the adaptations in 715 
the constriction motifs that enabled it. We consider that other pore-opening adaptations may 716 
have evolved in other organisms, including pathogens, which could initiate the 717 
pharmacological exploitation of aquaporins and lead to the design of new drug delivery 718 
strategies. 719 
 720 
  721 
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Materials and Methods 722 
Key Resources Table 
Reagent type 
(species) or 
resource 
Designation Source or 
reference 
Identifiers Additional 
information 
Cell line 
(Trypanosoma 
brucei) 
2T1 David Horn   
Cell line 
(Trypanosoma 
brucei) 
aqp2/aqp3 null David Horn   
Cell line 
(Trypanosoma 
brucei) 
aqp1-3 null David Horn   
Cell line 
(Trypanosoma 
brucei) 
CRK12 RNAi Tansy 
Hammarton 
  
Recombinant 
DNA reagent 
pRPa David Horn  plasmid for 
expression in T. 
brucei 
gene 
(Trypanosoma 
brucei) 
AQP2 TriTrypDB Tb927.10.1417
0 
Sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2S131P/S263A 
 
This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L258Y This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
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gene (Trypanosoma 
brucei) 
TbAQP2I110W 
 
This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L264R This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2I110W 
/L264R 
This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2I190T This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2W192G This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2I190T/W192G This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L84W This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L84M This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L118W This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L118M This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L218W This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP2L218M This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
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gene (Trypanosoma 
brucei) 
TbAQP2L84W/L118W This paper  Mutated TbAQP2; 
sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
AQP3 TriTrypDB Tb927.10.1416
0 
Sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP3W102I/R256L This paper  Sequence in 
Supplementary File 2 
gene (Trypanosoma 
brucei) 
TbAQP3W102I/R256L/Y
250L 
This paper  Sequence in 
Supplementary File 2 
Chemical 
compound, drug 
 All itemised in 
Supplementary 
File 1 
 Custom inhibitors and 
pentamidine 
analogues 
Chemical 
compound, drug 
Pentamidine 
isethionate 
Sigma-Aldrich   
Chemical 
compound, drug 
Diminazene 
aceturate 
Sigma-Aldrich   
Chemical 
compound, drug 
Suramin Sigma-Aldrich   
Chemical 
compound, drug 
Cymelarsan gift from C. 
Michael Turner 
  
Chemical 
compound, drug 
[3H]-pentamidine GE Healthcare 
Life Sciences 
 Radiochemical 
Chemical 
compound, drug 
[3H]-Suramin  American 
Radiolabeled 
Chemicals 
 Radiochemical 
Chemical 
compound, drug 
[3H]-glycerol American 
Radiolabeled 
 Radiochemical 
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Chemicals 
 723 
Trypanosome strains and cultures.  724 
The drug-sensitive clonal T. b. brucei strain 427 (MiTat 1.2/BS221) (De Koning et al, 2000) 725 
was used for all the work on the SAR of pentamidine transport. The tbaqp2/tbaqp3 null cells 726 
(Baker et al, 2012) and tbaqp1-2-3 null cells (Jeacock et al, 2017) (both obtained from David 727 
Horn, University of Dundee, UK) are derived from the 2T1 strain of T. b. brucei (Alsford & 728 
Horn, 2008). The CRK12 RNAi cell line
28
 was obtained from Dr Tansy Hammarton 729 
(University of Glasgow, UK) and is also based on the 2T1 cell line; RNAi expression was 730 
induced with 1 µg/ml tetracycline in the medium. All experiments were performed with 731 
bloodstream form trypanosomes grown in vitro in HMI-11 medium as described (Wallace et 732 
al, 2002) at 37 °C in a 5% CO2 atmosphere. Cultures were routinely maintained in 10 ml of 733 
this medium, being seeded at 5×10
4
 cells/ml and passed to fresh medium at reaching 734 
approximately 3×10
6
 cells/ml after 48 h. For transport experiments 150 or 200 ml of culture 735 
was seeded at the same density in large flasks and incubated until the culture reached late-log 736 
phase. 737 
 738 
Materials 739 
A complete list of diamidine analogues and other chemicals used for the SAR study is given 740 
as a table with their sources (Supplementary File 1). Ionophores and uncouplers nigericin, 741 
gramicidin, carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and valinomycin, as well as 742 
the T. brucei proton pump inhibitor N-ethylmaleimide (NEM) were all purchased from 743 
Sigma-Aldrich. New compounds synthesised for this study are listed and described in 744 
Supplementary File 3. 745 
 746 
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Transport assays - Transport of [
3
H]-pentamidine was performed exactly as previously 747 
described for various permeants (Wallace et al, 2002; Bridges et al, 2007; Teka et al, 2011) 748 
in a defined assay buffer (AB; 33 mM HEPES, 98 mM NaCl, 4.6 mM KCl, 0.55 mM CaCl2, 749 
0.07 mM MgSO4, 5.8 mM NaH2PO4, 0.3 mM MgCl2, 23 mM NaHCO3, 14 mM glucose, pH 750 
7.3). [
3
H]-pentamidine was custom-made by GE Healthcare Life Sciences (Cardiff, UK) with 751 
a specific activity of 88 Ci/mmol. Incubations of bloodstream form trypanosomes with 30 nM 752 
of this label (unless otherwise indicated) were performed in AB at room temperature for 60 s 753 
(unless otherwise indicated) and terminated by addition of 1 ml ice-cold ‘stop’ solution (1 754 
mM unlabelled pentamidine (Sigma) in AB) and immediate centrifugation through oil (7:1 755 
dibutylphthalate:mineral oil v/v (both from Sigma)). Transport was assessed in the presence 756 
of 1 mM adenosine to block uptake through the P2 aminopurine transporter; adenosine does 757 
not affect HAPT1-mediated transport (De Koning, 2001a; Bridges et al, 2007). Inhibition 758 
assays were performed routinely with 6 - 10 different concentrations of inhibitor over the 759 
relevant range, diluting stepwise by one third each time, in order to obtain a well-defined and 760 
accurate sigmoid plot and IC50 value (inhibitor concentration giving 50% inhibition of 761 
pentamidine transport; calculated by non-linear regression using Prism 6.0 (GraphPad), using 762 
the equation for a sigmoid curve with variable slope). Highest concentration was usually 1 763 
mM unless this was shown to be insufficient for good inhibition, or when limited by 764 
solubility. Ki values were obtained from IC50 values using  765 
Ki = IC50/[1 + (L + Km)]        (Eq. 1) 766 
in which L is the [
3
H]-pentamidine concentration and Km the Michaelis-Menten constant for 767 
pentamidine uptake by HAPT1 (Wallace et al, 2002). The Gibbs Free energy of interaction 768 
ΔG0 was calculated from 769 
ΔG0 = -RTlnKi         (Eq. 2) 770 
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in which R is the gas constant and T is the absolute temperature (Wallace et al, 2002). 771 
Transport of [
3
H]-glycerol and [
3
H]-suramin was performed essentially as for [
3
H]-772 
pentamidine. For [
3
H]-glycerol (American Radiolabeled Chemicals, 40.0 Ci/mmol), 10
7
 BSF 773 
T. brucei were incubated with radiolabel at a final concentration of 0.25 µM, for one minute. 774 
When the effect of CCP was studied, CCCP was added 3 minutes prior to the addition of the 775 
radiolabel. [
3
H]-suramin (American Radiolabeled Chemicals, 20.0 Ci/mmol) was also used at 776 
0.25 µM final concentration, using 15 min incubations in the presence and absence of 100 777 
µM unlabelled suramin (used as saturation) control. 778 
 779 
Construction of AQP mutants and transfection 780 
All mutations in the TbAQP2 and TbAQP3 genes were introduced to the relevant backbone 781 
WT vector, either pRPa
GFP-AQP2
 or pRPa
GFP-AQP3
 (Baker et al, 2012), by site-directed 782 
mutagenesis. Use of the pRPa vector for transfection of 2T1-derived T. brucei ensures 783 
integration in a prepared locus in the ribosomal rRNA spacer region and a high level of stable 784 
expression (Alsford et al, 2005). For mutations S131P, S263A, I110W, L264R, L258Y, 785 
I190T and W192G in AQP2, and W102I, R256L and Y250L in AQP3 mutations were 786 
inserted using the QuikChange II kit (Agilent, Santa Clara, CA, USA), following the 787 
manufacturer's instructions. For mutations L84W, L118W, L218W, L84M, L118M and   788 
L218M were introduced using the Q5 Site-Directed Mutagenesis Kit (E0554S), (New 789 
England BioLabs) according to manufacturer’s instructions. 790 
The following primer pairs (itemised in Supplementary File 4) were used to insert the 791 
named TbAQP2 mutations: for S131P, primers HDK1062 and HDK1063; in combination 792 
with mutation S263A, using primers HDK1064 and HDK1065 to produce plasmid 793 
pHDK166. For I110W, primers HDK607 and HDK608, to produce pHDK84; for L264R, 794 
primers HDK609 and HDK610 to produce pHDK167; the combination I110W/L264R was 795 
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produced using primers HDK609 and HDK610 on plasmid pHDK84 to give plasmid 796 
pHDK78; for L258Y, primers HDK1109 and HDK1110 to produce pHDK168; for I190T, 797 
primers HDK1056 and HDK1057 to produce pHDK163; for W192G, primers HDK1058 and 798 
HDK1059 to produce pHDK164; the combination I190T/W192G was produced using 799 
primers HDK1060 and HDK1061 on plasmid pHDK163 to give plasmid pHDK165; for 800 
L84W, primers HDK1276 and HDK1277, producing pHDK210; for L118W, primers 801 
HDK1274 and HDK1275, producing pHDK208; for L218W, primers HDK1272 and 802 
HDK1273, producing pHDK209; for the combination L84W/L118W, primers HDK1276 and 803 
HDK1277 on template pHDK208, producing pHDK227; for L84M, primers HDK1364 and 804 
HDK1367, producing pHDK234; for L118M, primers HDK1365 and HDK1367, producing 805 
pHDK235; and for L218M, primers HDK1366 and HDK1367, producing pHDK236. To 806 
insert the named mutations into TbAQP3, the following primers were used (Supplementary 807 
File 5): for W102I, primers HDK511 and HDK512, in combination with mutation R256L, 808 
with primers HDK513 and HDK514, to produce plasmid pHDK71; and to add mutation 809 
Y250L to this combination, primers HDK795 and HDK796, to produce pHDK121. All 810 
plasmids were checked by Sanger Sequencing (Source BioScience, Nottingham, UK) for the 811 
presence of the correct mutation(s) and the cassette for integration digested out with AscI 812 
(NEB, Hitchin, UK) prior to transfection. 813 
 For transfection, 10 µg of digested plasmid and 1-2×10
7
 parasites of the desired cell 814 
line (either aqp2/aqp3 null or aqp1/aqp2/aqp3 null) were resuspended in transfection buffer 815 
and transfected using an Amaxa Nucleofector, with program X-001. After a recovery period 816 
(8-16 h) in HMI-11 at 37 °C and 5% CO2, the parasites were cloned out by limiting dilution 817 
with the selection antibiotic (2.5 µg/ml hygromycin). In all cases the presence of the 818 
construct and its correct integration into the designed rRNA locus was verified by three PCR 819 
reactions, one using primers for the amplification of the full-length aquaporin 820 
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(primers HDK529 and HDK209). The second PCR was performed to amplify the gene with 821 
surrounding parts of the expression cassette using (primers HDK1011 and HDK430). The 822 
third PCR was to assess whether the expression cassette had linearized and integrated into 823 
the T. brucei genome using (primers HDK991 and HDK713).. 824 
 825 
Drug sensitivity assays 826 
Drug sensitivity assays for T. b. brucei bloodstream forms used the cell viability dye 827 
resazurin (Sigma) and were performed exactly as described (Wallace et al, 2002; Bridges et 828 
al, 2007) in 96-well plates with doubling dilutions of test compound, starting at 100 µM, over 829 
2 rows of the plate (23 dilutions plus no-drug control). Incubation time with test compound 830 
was 48 h (37 ºC/5% CO2), followed by an additional 24 h in the presence of the dye. 831 
 832 
Protein turnover and Western blotting 833 
 T. brucei 2T1 containing 
3×HA
AQP2 were incubated with 1 µg/ml tetracycline for 24 h at 37 834 
°C/5% CO2 to induce expression. Tetracycline was then washed away by four consecutive 835 
washes with fresh supplemented HMI-9, and cells were then incubated with 25 nM of 836 
pentamidine (5 × EC50) for 1h at 37 °C/5% CO2 prior to harvest cells for pulse chase 837 
experiments. To determine protein half-life, translation was blocked by addition of 838 
cycloheximide (100 µg/ml) and cells were harvested at various times by centrifugation (800 × 839 
g for 10 min at 4 °C). Cells were washed with ice-cold PBS, then resuspended in 1× SDS 840 
sample buffer (Thermo) and incubated at 70 °C for 10 min. Proteins were subjected to 841 
electrophoresis using 4-12% precast acrylamide Bis-Tris gels (Thermo) and transferred to 842 
polyvinylidene difluoride (PVDF; Sigma-Aldrich) membranes with a iBlot2 system (Thermo) 843 
at 23 V for 6 min, exactly as described (Quintana et al, 2020), blocking non-specific binding 844 
with 5% (w/v) bovine serum albumin (BSA; Sigma) in Tris-buffered saline (pH 7.4) with 845 
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0.2% (v/v) Tween-20 (TBST) and using rat anti-HA IgG1 (Sigma) or anti-mouse β-tubulin 846 
(clone KMX-1; Millipore) at 1:5,000 or 1:10,000 dilution in TBST, respectively. Membranes 847 
were washed 5 times with TBST and then incubated in TBST/1% BSA with the appropriate 848 
horseradish peroxidase (HRP)-coupled secondary antibody (Sigma), at 1: 10,000. Bands were 849 
visualised using the ECL Prime Western Blotting System (Sigma) and GE healthcare 850 
Amersham Hyperfilm ECL (GE). Densitometry quantification was conducted using ImageJ 851 
software (NIH).  852 
 853 
Molecular dynamics 854 
Molecular dynamics simulations were performed using the GROMACS software package, 855 
version 5.1.1 (Abraham et al, 2015). We used the coordinates from the homology model of 856 
TbAQP2 published in Figure 2A in Munday et al (2015a), which was inserted into 857 
POPC/POPE (4:1) membranes, approximately reflecting the membrane composition of T. b. 858 
brucei (Smith & Bütikofer, 2010). The membrane models were constructed using the 859 
CHARMM-GUI webserver (Jo et al, 2008). Subsequently, extended stability tests of the 860 
modelled structure and the bound pentamidine were carried out using unbiased simulations of 861 
100 ns length. The root-mean-square deviation (RMSD) of the protein remained relatively 862 
low with a backbone RMSD converging to ~3 Å after 100 ns simulated time (Figure 8-figure 863 
supplement 1) bound to the binding site defined previously using molecular docking (Figure 864 
8A) (Munday et al, 2015a). For these and all following simulations, we used the 865 
CHARMM36 force field (Klauda et al, 2010); pentamidine was parameterised using the 866 
CHARMM generalized force field approach (CHGenFF (Vanommeslaeghe et al, 2010)). All 867 
simulations employed a time step of 2 fs under an NPT ensemble at p = 1 bar and T = 310 K. 868 
To obtain non-equilibrium work values for removing pentamidine from the internal AQP2 869 
binding site, we then conducted steered MD simulations with a probe speed of 0.005 nm/ns 870 
 41 
and a harmonic force constant of 300 kJ/mol nm
2
, pulling pentamidine in both directions 871 
along the pore axis. The free energy profile of pentamidine binding to the AQP2 pore was 872 
reconstructed by using the Jarzynski equality (Jarzynski, 1997). 873 
 874 
Statistical analysis 875 
All transport experiments were performed in triplicate and all values such as rate of uptake, 876 
percent inhibition, Ki, Km, Vmax etc were performed at least three times completely 877 
independently. For drug sensitivity tests, all EC50 values were based on serial dilutions over 878 
two rows of a 96-well plate (23 doubling dilutions plus no-drug control), which were 879 
obtained independently at least three times. EC50 and IC50 values were determined by non-880 
linear regression using the equation for a sigmoid curve with variable slope and are presented 881 
as average ± SEM. Statistical significance between any two data points was determined using 882 
Student’s t-test (unpaired, two-tailed).  883 
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Figures and Legends 1175 
 1176 
 1177 
Figure 1. Phylogenetic tree of Trypanosoma aquaporins. The tree is a Neighbour-joining 1178 
tree produced in Clustal Omega with the lengths of the horizontals proportional to the 1179 
differences. 1180 
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QLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLSITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVF1240 
GCFPWRRVPGYIAAQMLGAFVGAACAYGVYADLLKQHSGGLVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTA1241 
ILLFCVGGIFDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGNYYFWVP1242 
LFIPFLGGIFGLFLYKYFVPY 1243 
 1244 
>Tbr AQP2 1245 
MQSQPDNVAYPMELQAVNKDGTVEVRVQGNVDNSSNERWDADVQKHEVAEAQEKPVGGINFWAPRELRLNYRDYV1246 
AEFLGNFVLIYIAKGAVITSLLVPDFGLLGLTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPG1247 
YIAAQMLGTFLGAACAYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI1248 
FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHANYYFWVPLVVPFFGAI1249 
LGLFLYKYFLPH 1250 
 1251 
>Tbr AQP3 1252 
MQSQPDNVAYPMELQAVNKDGTVEVRVQGNDDSSNRKHEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFV1253 
LLFMGNGVVATVIIDGKLGFLSITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLG1254 
AFLGAACAYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGIFDPNNSPA1255 
KGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHANYYFWVPLVIPLFGGIFGLFLYKY1256 
FVPH 1257 
 1258 
>Tsu AQP1 1259 
MSSEPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVKAGGGEAEVQNAADVNNW1260 
APRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLSITLGWGIAVTMGLYISLGTSCGHLNPAVTVAN1261 
AVFGCFPWKKVAGYIAMQMLGAFVGAACAYGVFADLLKQHSGGLIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFI1262 
CTAMLLFCVSGIFDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGNYYF1263 
WVPLFIPFLGGIFGLLLYKYFVPH 1264 
 1265 
>Tsu AQP2 1266 
MQNQPDAMTHSTAVQMVNKNPEDGTGGADTERSDEMTAPTTRTGDAQKCETTNTPKEGAGGINYWAPRELRLKYR1267 
DYMGELLGTFVLLLMGNGVVATVVVDGKLGFLSITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRK1268 
VPGYIAAQMFGAFLGAACAYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCV1269 
CGIFDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGNYYFWVPLFIPFL1270 
GAIFGLFLYKYFVPH 1271 
 1272 
Figure 1-figure supplement 1. Sequence alignment and individual sequences of the T. 1273 
congolense, T. b. brucei and T. suis. The T. brucei and T. congolense sequences were 1274 
 57 
obtained from tritrypDB, T. suis sequences  (Kelly S, Gibson W and Carrington M. The 1275 
genome of Trypanosoma suis. In preparation). The alignment was produced with Clustal 1276 
Omega. The yellow highlighting indicates the N-terminus of the sequences used to determine 1277 
non-synonymous v synonymous ratios. 1278 
 1279 
 1280 
dN/dS 1281 
 1282 
T. brucei AQP1 v T. suis AQP1   0.21 1283 
T. brucei AQP3 v T. suis AQP3  0.30 1284 
T. brucei AQP2 v T. brucei AQP3  2.00 1285 
 1286 
Figure 1-figure supplement 2. The ratio of non-synonymous v synonymous (dN/dS) codon 1287 
changes calculated for selected comparisons between T. brucei and T. suis AQPs. The ratios 1288 
were calculated using a region of high confidence alignments from ~amino acid 60 1289 
(highlighted in Figure 1-figure supplement 1) to the C-terminus. 1290 
 1291 
 1292 
 58 
 1293 
Figure 2. The selectivity filter differences between TbAQP2 and TbAQP3 are largely 1294 
responsible for their differences in pentamidine sensitivity and transport rates.  1295 
(A) Transport of 30 nM [
3
H]-pentamidine by tbaqp2/aqp3 null cells expressing TbAQP2-WT 1296 
or one of the TbAQP2 mutants as indicated (blue bars). The corresponding brown bars are 1297 
pentamidine transport in the control tbaqp2/aqp3 null cells assessed in parallel in each 1298 
 59 
experiment. Transport was determined in the presence of 1 mM adenosine to block the 1299 
TbAT1/P2 transporter. Bars represent the average and SEM of at least three independent 1300 
experiments, each performed in triplicate. Blue stars: statistical significance comparison, by 1301 
two-tailed unpaired Student’s tests, between the cells expressing TbAQP2WT and mutants; 1302 
red stars: statistical comparison between the AQP2-expressing cells and control cells; NS, not 1303 
significant. (B-F) EC50 values indicated test drugs, expressed as a percentage of the resistant 1304 
control (tbaqp2/tbaqp3 null), against cell lines either expressing the indicated TbAQP2 1305 
mutant or TbAQP2WT (sensitive control). Red stars and green stars: comparison with 1306 
tbaqp2/aqp3 null or TbAQP2WT-expressing cells, respectively, which were always assessed 1307 
in parallel in each experiment. (G) Transport of 30 nM [
3
H]-pentamidine by tbaqp2/aqp3 null 1308 
cells expressing TbAQP3 or an AQP3 mutant as indicated. (H) EC50 values of the indicated 1309 
drugs against tbaqp2/aqp3 null cells expressing either TbAQP3 or a mutant thereof, 1310 
expressed as percentage of tbaqp2/aqp3 null. All data for these graphs are contained in the 1311 
source file Figure2-Source data.xlsx. 1312 
All experiments are the average and SEM of at least 3 independent experiments. *, P<0.05; 1313 
**, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test, two-tailed.  1314 
 1315 
 60 
 1316 
Figure 3. Mutational analysis of TbAQP2 residues I190 and W192. (A) Transport of 30 1317 
nM [
3
H]-pentamidine by tbaqp2/tbaqp3 null cells or TbAQP2 variants expressed therein. 1318 
Transport was expressed as a percentage of the rate of the AQP2WT control, performed in 1319 
parallel. Blue stars are comparison with TbAQP2WT, red stars, comparison with the 1320 
tbaqp2/tbaqp3 null control. NS, not significant. (B) EC50 values for the indicated drugs 1321 
against tbaqp2/tbaqp3 null cells, and against TbAQP2WT and TbAQP2
I190T
 expressed 1322 
therein; values were expressed as % of the tbaqp2/tbaqp3 null (resistant) control. Red stars, 1323 
comparison with the resistant control; green stars, comparison with the internal sensitive 1324 
control (TbAQP2WT). The assays for all three strains and all three drugs were done 1325 
simultaneously on at least 3 different occasions. (C) As B but for TbAQP2
W192G
. (D) As B 1326 
but for TbAQP2
I190T/W192G
. All data for these graphs are contained in the source file Figure3-1327 
Source data.xlsx. 1328 
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*, P<0.05; **, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test. 1329 
 1330 
Figure 3-figure supplement 1. Pentamidine transport analysis for TbAQP2
I190T
 and 1331 
TbAQP2WT. (A) Transport of 30 nM [
3
H]-pentamidine by tbaqp2/tbaqp3 null cells 1332 
expressing TbAQP2
I190T
, in the presence of unlabelled pentamidine at the indicated 1333 
concentrations. Incubation time was 15 min, required to ensure sufficient radiolabel for 1334 
accurate quantification, and uptake was linear and through zero over this period. The 1335 
inhibition data were plotted to a double sigmoidal curve (Prism 7.0) with the bottom value 1336 
fixed at 0. The high affinity component displayed an average an IC50 of 30.9 ± 12.2 nM (n=3) 1337 
and the lower affinity segment could be converted to a Michaelis-Menten plot for 1338 
determination of Km and Vmax (inset), yielding an average Km of 59.9 ± 9.1 µM (n=3), 1339 
consistent with the Low Affinity Pentamidine Transporter (LAPT1; Bridges et al, 2007). The 1340 
 62 
plot shown is one representative experiment in triplicate of three independent experiments. 1341 
(B) Like (A) but with tbaqp2/tbaqp3 null cells expressing TbAQP2WT. Incubation time was 1342 
20 s (linear phase). The high affinity phase had statistically identical EC50 (41 ± 17 nM; 1343 
P>0.05) as TbAQP2
I190T
. The inset shows a zoom-in on the low-affinity part of the curve 1344 
(LAPT1 contribution), with the dotted line representing a theoretical sigmoid plot for 1 1345 
inhibitor, with the upper limit fixed at the value obtained for 10 μM pentamidine. The low 1346 
affinity component was also statistically identical in the two strains (TbAQP2-WT Km = 82.7 1347 
± 17.5 µM (n=3; P>0.05)). Note that the amount of [
3
H]-pentamidine taken up by the low 1348 
affinity component is highly similar for the mutant (A) and control (B) cell lines, at 1349 
approximately 0.0005 pmol(10
7
 cells)
-1
s
-1
. Both frames show one representative experiment 1350 
of three repeats, each performed in triplicate. Error bars are SEM, when not shown, fall 1351 
within the symbol. All data for these graphs are contained in the source file Figure3-Source 1352 
data.xlsx.  1353 
 63 
 1354 
Figure 4. Analysis of TbAQP2 variants with a leucine-to-tryptophan or leucine-to-1355 
methionine substitution near the cytoplasmic end of the pore. (A) Pentamidine EC50 1356 
values (nM) for mutant and WT TbAQP2 expressed in tbaqp2/tbaqp3 cells (aqp2-3 null). The 1357 
mutants are either a Trp (dark blue bars) or Met (orange bars) substitution at the indicated 1358 
positions. The resistant control (aqp2-3 null) and sensitive control (AQP2WT) for the 1359 
separate datasets (Trp or Met) are indicated as hatched bars in the same colours. (B) As (A) 1360 
but showing transport of 30 nM [
3
H]-pentamidine by the same cell lines, expressed as 1361 
percentage of the transport rate in the TbAQP2 control cells. (C) Pentamidine EC50 values for 1362 
the same mutants as in (A) but expressed in the tbaqp1-2-3 null cells, performed in parallel 1363 
with the determination of EC50 values for SHAM, shown in (D). As all cell lines were done 1364 
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simultaneously, the resistant and sensitive strain control values are identical for the Trp and 1365 
Met mutants in this series.  1366 
All bars represent the average and SEM of at least three independent replicates. *, P<0.05; 1367 
**, P<0.01; ***, P<0.001, ****, P<0.0001 by unpaired Student’s t-test; ns, not significant; 1368 
nd, not determined. All data for these graphs are contained in the source file Figure4-Source 1369 
data.xlsx. 1370 
 1371 
 1372 
Figure 4-figure supplement 1. EC50 values for Cymelarsan, diminazene aceturate and 1373 
phenylarsine oxide (PAO) against the tbaqp2-tbaqp3 null cell line. AQP2-WT and various 1374 
 65 
mutant versions thereof (indicated) were expressed in this cell line. EC50 values were 1375 
determined using the alamar blue (resazurin) assay. Bars represent  the average and SEM for 1376 
at least three determinations. nd, not done. All data for these graphs are contained in the 1377 
source file Figure4-Source data.xlsx. 1378 
 1379 
 1380 
Figure 4-figure supplement 2. Correlation of the EC50 value with the rate of pentamidine 1381 
transport for all 19 cell lines expressing a wild-type or mutant TbAQP2 in the aqp2/3 null T. 1382 
b. brucei line. All EC50 values are expressed as percentage of the resistant control, aqp2/3 1383 
null transfected with an empty vector (no TbAQP2). 2T1 is the parental cell line of the 1384 
aqp2/3 null. All values are the average of at least three independent determinations; the 1385 
sensitive and resistant control cell lines were included in each independent experiment and 1386 
the percentages taken are from the internal control rather than from the grand average over all 1387 
experiments. All data for these graphs are contained in the source file Figure4-Source 1388 
data.xlsx.  1389 
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Figure 5. Disabling endocytosis does not reduce uptake of pentamidine. (A) qRT-PCR of 1391 
CRK12, normalised to housekeeping gene GPI-8 (n=3). (B) Transport of 0.025 µM [
3
H]-1392 
Pentamidine measured in control (non-induced) and CRK12 cell after exactly 12 h of 1393 
tetracycline induction; incubation time with label was 30 s. Bar is average and SEM of 5 1394 
independent determinations, each performed in triplicate. NS, not significant by unpaired 1395 
Student’s t-test. (C) As frame B but uptake of 0.25 µM [3H]-suramin over 15 min; average 1396 
and SEM of 5 independent determinations, each in quadruplicate. **, P=0.0027 by Student’s 1397 
unpaired, two-tailed t-test. All data for these graphs are contained in the source file Figure5-1398 
Source data.xlsx. 1399 
 1400 
 1401 
Figure 5-figure supplement 1. Growth Curve of CRK12 RNAi cells in full HMI-9 medium 1402 
at 37 ºC/5% CO2, in the presence or absence of 1 μg/ml tetracycline (tet). Cell counts were 1403 
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performed with a haemocytometer and the average of duplicate determinations is shown. All 1404 
data for these graphs are contained in the source file Figure5-Source data.xlsx. 1405 
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Figure 6. Quantification of Western blots of 
3×HA
TbAQP2. Cells were induced for expression 1407 
of 
3×HA
TbAQP2, pretreated with cyclohexidine and subsequently with 25 nM pentamidine 1408 
(5× EC50). Western blots (figure supplement 1) were performed using anti-HA antiserum in 1409 
order to quantify the relative amount of TbAQP2 in the cells. The two datasets were not 1410 
significantly different by Kolmogorov-Smirnov test (P=0.77) and data points at each time 1411 
point were also not significantly different by Student’s t-test (P>0.05). All data for these 1412 
graphs are contained in the source file Figure6-Source data.xlsx. 1413 
 1414 
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 1415 
Figure 6-figure supplement 1. Western blots for a 
3xHA
AQP2 turnover assay in untreated T. 1416 
brucei 2T1 cells, or in the presence of pentamidine 25 nM. Two independent experiments are 1417 
shown. HA, haemagglutinin; tub, β-tubulin; CHX, cycloheximide; α-HA, anti-HA serum. All 1418 
data for these graphs are contained in the source file Figure6-Source data.xlsx.  1419 
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 1420 
 1421 
Figure 7. High affinity pentamidine uptake in T. b. brucei is sensitive to ionophores. (A) 1422 
Uptake of 25 nM [
3
H]-pentamidine in s427WT bloodstream forms was measured in the 1423 
presence of 1 mM adenosine to block the P2 transporter, and in the further presence of 1424 
various ionophores at the indicated concentrations in µM. Incubation with radiolabel was 5 1425 
min after a 3 min pre-incubation with ionophore. Accumulation of radiolabel was expressed 1426 
as a percentage of the control, being a parallel incubation in the absence of any ionophore. 1427 
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Bars represent the average of 3 – 5 independent determinations (each performed in 1428 
quadruplicate) and SEM. (B) Uptake of 0.25 µM [
3
H]-suramin by T. b. brucei s427WT cells 1429 
over 10 minutes. Cells were incubated in parallel, with or without the presence of 20 µM 1430 
CCCP (plus 3-minute pre-incubation). Saturation of the suramin-receptor interaction was 1431 
demonstrated by including 100 µM unlabelled suramin (blue bars). Bars represent average 1432 
and SEM or three independent experiments, each performed in quadruplicate. (C) Correlation 1433 
plot of pentamidine transport rate versus protonmotive force (PMF), r
2
 = 0.93, P<0.05 by F-1434 
test. Concentrations in µM are indicated in the frame. CCCP is shown in red and not included 1435 
in the regression analysis. Each data point is the average of 4 or more independent repeats 1436 
performed in quadruplicate. The values for PMF were taken from (De Koning and Jarvis, 1437 
1997b). (D) Uptake of 0.25 µM [
3
H]-glycerol by aqp1/aqp2/aqp3 null cells expressing 1438 
TbAQP2-WT. Dose response with CCCP and pentamidine (PMD), using an incubation time 1439 
of 1 min. The graph shown was performed in triplicate and representative of three 1440 
independent repeats. (E) As D but using 0.025 µM [
3
H]-pentamidine and 30 s incubations. 1441 
Representative graph in triplicate from 3 independent repeats.  1442 
*, P<0.05; **, P<0.01; ***, P<0.001 by Student’s unpaired t-test. All data for these graphs 1443 
are contained in the source file Figure7-Source data.xlsx.  1444 
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 1445 
Figure 8. Pentamidine binding in TbAQP2 and free-energy profile of permeation (Left). 1446 
A. Docked conformation of pentamidine (blue) bound to the TbAQP2 (wheat). The protein 1447 
and the ligand were modelled as described.
4
 The protein pore is shown in grey mesh, and the 1448 
mutated positions described in the text are in magenta. (Right) Free-energy profile G(L) 1449 
(solid blue line) along the pore axis of TbAQP2 (L). The membrane voltage of T. b. brucei 1450 
gives rise to a voltage drop across the membrane (gray dotted line), which alters the free-1451 
energy profile (dashed blue line includes Vm effect) and reduces the free-energy of 1452 
pentamidine exit into the intracellular bulk by ~22 kJ/mol as compared to the extracellular 1453 
side (black arrow). 1454 
A 
B 
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B. Close-up views comparing the bound positions of pentamidine (left) and melarsoprol 1455 
(right) and showing the mutated sites and major interactions with the AQP2 pore lining. 1456 
 1457 
 1458 
Figure 8-figure supplement 1. Backbone RMSD of the protein inserted into a lipid bilayer 1459 
showing convergence to ~3 Å in a simulation of 100 ns length.  1460 
  1461 
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 1462 
 1463 
 74 
Figure 9. Correlation between linker chain length and affinity to HAPT1. 1464 
(A) A series of pentamidine analogues with different methylene linker length was tested for 1465 
inhibition of TbAQP2/HAPT1-mediated 25 nM [
3
H]-pentamidine transport (i.e. in the 1466 
presence of adenosine to block the TbAT1/P2 transporter). The Ki values are listed in Table 1467 
1. All Ki values are shown as average and SEM of 3 or more independent experiments, each 1468 
performed in triplicate. (B) The distance between the amidine carbon atoms in the lowest-1469 
energy conformation was calculated using density functional theory as implemented in 1470 
Spartan ’16 v2.0.7. Geometry optimisations were performed with the wB97XD functional 1471 
and the 6-31G* basis set at the ground state in gas phase. Structures and distances shown 1472 
represent the dication state that is overwhelmingly prevalent in aqueous solution at neutral 1473 
pH. The numbered red data points correspond to the propamidine - octamidine series in frame 1474 
A. (C) Repulsion between free electron pairs (double dots), indicated by curved blue lines for 1475 
RT-52 in the cis-conformation, causing it to exist overwhelmingly in the anti-conformation. 1476 
(D) Overview of SAR observations on the binding preferences of TbAQP2 for pentamidine 1477 
and its analogues. All data for these graphs are contained in the source file Figure9-Source 1478 
data.xlsx. 1479 
 1480 
 75 
Figure 9-figure supplement 1. Correlation between the Resistance Factor (RF; EC50(aqp2/3 1481 
null)/EC50(TbAQP2-WT)) and the Ki value for inhibition of the High Affinity Pentamidine 1482 
Transporter (HAPT1) encoded by TbAQP2. The pentamidine value (bold) is the Km 1483 
determined with radiolabeled pentamidine. The table lists the data points shown in the plot. 1484 
The line was made by linear regression (Prism 6.0); correlation coefficient r
2
 is 0.037. F-test: 1485 
slope is not significantly different from zero (P = 0.33). All values are in µM. All data for 1486 
these graphs are contained in the source file Figure9-Source data.xlsx. 1487 
 1488 
Supplementary File 1. Table of all HAPT/TbAQP2 inhibitors used in this study 1489 
Supplementary File 2. Table with all sequences of TbAQP2 and the generated mutants 1490 
thereof. Mutated nucleotides and codons are indicated.  1491 
Supplementary File 3. Synthesis of all new inhibitors used in this study. 1492 
Supplementary File 4. List of primers used in the construction of mutations in TbAQP2. 1493 
Supplementary File 5. Primers used for mutations in TbAQP3. 1494 
 1495 
  1496 
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Table 1. Pentamidine analogues with an aliphatic linker 1497 
 1498 
Compound R1 R2 R3 R4 X Y Z 
Ki 
(µM) 
δ(ΔG0) 
PMD 
(kJ/mol) 
Ethamidine Am Am H H CH CH -O-(CH2)2-O- >100 >19.7 
Propamidine Am Am H H CH CH -O-(CH2)3-O- 6.63 ± 1.40 13.0 
Butamidine Am Am H H CH CH -O-(CH2)4-O- 3.87 ± 1.38 11.7 
Pentamidine 
(PMD) 
Am Am H H CH CH -O-(CH2)5-O- 
0.036 ± 
0.0006 
-- 
Hexamidine Am Am H H CH CH -O-(CH2)6-O- 
0.058 ± 
0.011 
1.3 
Heptamidine Am Am H H CH CH -O-(CH2)7-O- 
0.123 ± 
0.010 
3.1 
Octamidine Am Am H H CH CH -O-(CH2)8-O- 2.16 ± 0.48 10.2 
RT-48 Am Am H H CH CH -S-(CH2)5-S- 2.01 ± 0.86 10.0 
RT-50 Am Am H H 
CH CH -NH-(CH2)5-
NH- 
6.27 ± 1.30 12.9 
RT-49 Am Am H H 
CH CH -SO2-(CH2)5-
SO2- 
>150 >20.7 
DB1699 Am Am H H CH CH -O-(CH2)2-O- 16.6 ± 2.1 15.3 
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(CH2)2-O- 
RT-36 Am NH2 H H CH CH -O-(CH2)5-O- 0.43 ± 0.07 6.2 
CHI/1/72/1 Am CH3 H H CH CH -O-(CH2)5-O- 3.1 ± 0.7 10.7 
CHI/1/69/1 Am H H H CH CH -O-(CH2)4-O- 2.3 ± 0.5 10.4 
RT-38 Am CA H H CH CH -O-(CH2)3-O- NI, 100 >19.7 
meta-PMD H H Am H 
CH CH 
-O-(CH2)5-O- 
2890 ± 
1050 
28.1 
RT-32 Im Im H H CH CH -O-(CH2)5-O- 0.40 ± 0.08 6.0 
RT-30 MeAm MeAm H H CH CH -O-(CH2)5-O- 0.30 ± 0.07 5.3 
Stilbamidine Am Am H H CH CH -CH=CH- 54.8 ± 3.2 18.3 
FR39 G1 G1 H H CH CH -(CH2)2- 41.7 ±15.2 17.6 
CRMI8 G2 G2 H H CH CH -(CH2)2- 52.8 ±12.7 18.1 
RT-43 Am  Am H Cl CH CH -O-(CH2)5-O- 0.51 ± 0.15 6.6 
Iodo-PMD Am  Am H I CH CH -O-(CH2)5-O- 2.15 ± 0.04 8.4 
RT-46 Am  Am H -C(O)NH2 CH CH -O-(CH2)5-O- >100 >19.7 
RT-52 Am Am H H CH N -O-(CH2)5-O- 8.84 ± 0.88 13.7 
RT-53 Am Am H H N CH -O-(CH2)5-O- NI, 250 >22 
Am, amidine; MeAm, Methyl-amidine; Im, imidazole; CA, carboxylic acid; G1, 2-1499 
aminoimidazoline; G2, 1-methoxy-2-aminoimidazoline. PMD, pentamidine, NI, no inhibition 1500 
at the indicated concentration in µM. Ki is the inhibition constant for [
3
H]-pentamidine 1501 
transport by TbAQP2/HAPT1. δ(ΔG0) PMD is the difference in Gibbs Free Energy of 1502 
interaction of the substrate with TbAQP2 with the same value for pentamidine (PMD). All Ki 1503 
values are the average and SEM of at least 3-4 independent experiments. 1504 
  1505 
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Table 2. Selection of diamidine analogues with aromatic linkers 1506 
 1507 
Compound R1 R2 Ar X Y 
Ki 
(µM) 
δ(ΔG0) 
PMD 
(kJ/mol) 
DB75 Am Am 
 
CH CH 38.2 ± 10.2 17.3 
DB607 Am OCH3 
 
CH CH 18.1 ± 1.9 15.5 
DB960 Am NMB
a
 
 
CH CH 16.6 ± 3.5 15.3 
DB994 Am Am 
 
N CH 167 ± 20 21.0 
DB829 Am Am 
 
CH N 39.9 ± 8.0 17.4 
DB1061 EtAm EtAm 
 
CH CH 32.3 ± 6.0 16.9 
DB1062 2MeIm 2MeIm 
 
CH CH 59.6 ± 11.2 18.4 
ER1004 Am Am 
 
CH CH 68.7 ± 16.0 18.8 
DB320 Am Am 
 
CH CH 71.3 ± 12.1 18.9 
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DB686 Gua Gua 
 
CH CH 0.29 ± 0.11 5.2 
DB1063 EtAm EtAm 
 
CH CH 0.40 ± 0.10 6.0 
DB1064 2MeIm 2MeIm 
 
CH CH 3.0 ± 0.82 11.0 
DB1213 Am Am 
 
CH CH 0.72 ± 0.17 7.5 
DB1077 Am Am 
 
CH CH 13.8 ± 3.1 14.8 
DB914 Am Am 
O
O
 
CH CH 
0.073 ± 
0.013 
1.8 
Am, amidine; Im, imidazole; EtAm, ethylamidine; 2MeIm, 2-methylimidazoline; NMB, N-1508 
methyl benzimidazole. 
a
This compound lacks the second benzene ring and features the 1509 
terminal NMB moiety instead. Ki is the inhibition constant for [
3
H]-pentamidine transport by 1510 
TbAQP2/HAPT1. δ(ΔG0) PMD is the difference in Gibbs Free Energy of interaction of the 1511 
substrate with TbAQP2 with the same value for pentamidine (PMD). All Ki values are the 1512 
average and SEM of at least 3-4 independent experiments. 1513 
 1514 

Tco       MTSPTVPNPMSTVPMTEM----TE-ANGTTNPPIPDAGERTAV---NFDTEQCK-TKEIL 51 
Tbr1      MSD--EKINVHQYPSETDVRGLKARNGGACEVPFEENN-EPIPNRSANPQEKNE--NELV 55 
Tsu1      MSS--EPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVK 58 
Tsu2      MQN--QPDAMTH-STAVQMV-NKNPEDGTGGADTERSDEMTAP--------TTRTGDAQK 48 
Tbr2      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNVDNSSN--------ERWDADVQK 45 
Tbr3      MQS--QPDNVAY-PMELQAV-NKDGT---VEVRVQGNDDSS----------------NRK 37 
          * .      :            .                                      
 
Tco       -AGEGEAPHGPMDINYWPLRNLRMDFREYVGEFLGTFVLLFMGNGVVATTLLDNNLGFLS 110 
Tbr1      GDNADNEAHDAVDVNYWAPRQLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLS 115 
Tsu1      AGGGEAEVQNAADVNNWAPRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLS 118 
Tsu2      CETTNTPKEGAGGINYWAPRELRLKYRDYMGELLGTFVLLLMGNGVVATVVVDGKLGFLS 108 
Tbr2      HEVAEAQEKPVGGINFWAPRELRLNYRDYVAEFLGNFVLIYIAKGAVITSLLVPDFGLLG 105 
Tbr3      HEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFVLLFMGNGVVATVIIDGKLGFLS 97 
                  .   .:* *  *.**:.:*:*:.*:**.***: :.:*.* * ::   :*:*. 
 
Tco       ITFGWGIAVTMGLYVSLGTSSGHLNPAVTVANAFFGGFPWKKVPGYIAMQMLGAFVGAAC 170 
Tbr1      ITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVFGCFPWRRVPGYIAAQMLGAFVGAAC 175 
Tsu1      ITLGWGIAVTMGLYISLGTSCGHLNPAVTVANAVFGCFPWKKVAGYIAMQMLGAFVGAAC 178 
Tsu2      ITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMFGAFLGAAC 168 
Tbr2      LTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPGYIAAQMLGTFLGAAC 165 
Tbr3      ITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLGAFLGAAC 157 
          :*:* *:****.**:*** * **** ***:.**.** ***::* **** **:*:*:**** 
 
Tco       AYGVYADLLNKKVSDG----EIEDYAGMFSTYPRDGNSLFSCIFGEFICTAMLTFCVCGI 226 
Tbr1      AYGVYADLLKQHSGG-LVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTAILLFCVGGI 234 
Tsu1      AYGVFADLLKQHSGG-LIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFICTAMLLFCVSGI 237 
Tsu2      AYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCVCGI 228 
Tbr2      AYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI 225 
Tbr3      AYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGI 217 
          ****:****:   ..       :. * :*: ** :.* :*  :*.*:*.**:* :** ** 
 
Tco       FDTHNAPATGHEPLAVGALVFAIGNNVGYATGYAINPARDFGPRVFSAILYGSTVFTRGD 286 
Tbr1      FDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGN 294 
Tsu1      FDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGN 297 
Tsu2      FDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGN 288 
Tbr2      FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHAN 285 
Tbr3      FDPNNSPAKGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHAN 277 
          ** :*:**. :* :*:*:*:*.: **.* ::  *:**: **.**:*.::* *. **: .: 
 
Tco       YYFWVPLFIPLLGGIFGIILYKYFVPH 313 
Tbr1      YYFWVPLFIPFLGGIFGLFLYKYFVPY 321 
Tsu1      YYFWVPLFIPFLGGIFGLLLYKYFVPH 324 
Tsu2      YYFWVPLFIPFLGAIFGLFLYKYFVPH 315 
Tbr2      YYFWVPLVVPFFGAILGLFLYKYFLPH 312 
Tbr3      YYFWVPLVIPLFGGIFGLFLYKYFVPH 304 
          *******.:*::*.*:*::*****:*: 
 
Figure 1-figure supplement 1. Sequence alignment and individual sequences of the T. 
congolense, T. b. brucei and T. suis. The T. brucei and T. congolense sequences were 
obtained from tritrypDB, T. suis sequences  (Kelly S, Gibson W and Carrington M. The 
genome of Trypanosoma suis. In preparation). The alignment was produced with Clustal 
Omega. The yellow highlighting indicates the N-terminus of the sequences used to determine 
non-synonymous v synonymous ratios. 
 
>Tco AQP1 
MTSPTVPNPMSTVPMTEMTEANGTTNPPIPDAGERTAVNFDTEQCKTKEILAGEGEAPHGPMDINYWPLRNLRMD
FREYVGEFLGTFVLLFMGNGVVATTLLDNNLGFLSITFGWGIAVTMGLYVSLGTSSGHLNPAVTVANAFFGGFPW
KKVPGYIAMQMLGAFVGAACAYGVYADLLNKKVSDGEIEDYAGMFSTYPRDGNSLFSCIFGEFICTAMLTFCVCG
IFDTHNAPATGHEPLAVGALVFAIGNNVGYATGYAINPARDFGPRVFSAILYGSTVFTRGDYYFWVPLFIPLLGG
IFGIILYKYFVPH 
 
>Tbr AQP1 
MSDEKINVHQYPSETDVRGLKARNGGACEVPFEENNEPIPNRSANPQEKNENELVGDNADNEAHDAVDVNYWAPR
QLRLDYRNYMGEFLGTFVLLFMGNGVVATTILDKDLGFLSITLGWGIAVTMGLYISLGISCGHLNPAVTLANAVF
GCFPWRRVPGYIAAQMLGAFVGAACAYGVYADLLKQHSGGLVGFGDKGFAGMFSTYPREGNRLFYCIFSEFICTA
ILLFCVGGIFDPNNSPAKGHEPLAVGALVFAIGNNIGYASGYAINPARDFGPRVFSAILFGSEVFTTGNYYFWVP
LFIPFLGGIFGLFLYKYFVPY 
 
>Tbr AQP2 
MQSQPDNVAYPMELQAVNKDGTVEVRVQGNVDNSSNERWDADVQKHEVAEAQEKPVGGINFWAPRELRLNYRDYV
AEFLGNFVLIYIAKGAVITSLLVPDFGLLGLTIGIGVAVTMALYVSLGISGGHLNSAVTVGNAVFGDFPWRKVPG
YIAAQMLGTFLGAACAYGVFADLLKAHGGGELIAFGEKGIAWVFAMYPAEGNGIFYPIFAELISTAVLLLCVCGI
FDPNNSPAKGYETVAIGALVFVMVNNFGLASPLAMNPSLDFGPRVFGAILLGGEVFSHANYYFWVPLVVPFFGAI
LGLFLYKYFLPH 
 
>Tbr AQP3 
MQSQPDNVAYPMELQAVNKDGTVEVRVQGNDDSSNRKHEVAEAQEEVPGGINFWAPRELRLNYRDYMGELLGTFV
LLFMGNGVVATVIIDGKLGFLSITLGWGIAVTMALYVSLGISSGHLNPAVTVGNAVFGDFPWRKVPGYIAAQMLG
AFLGAACAYGVFADLLKAHGGGELIAFGEKGTAGVFSTYPRDSNGLFSCIFGEFICTAMLLFCVCGIFDPNNSPA
KGHEPLAVGALVFAIGNNIGYSTGYAINPARDFGPRVFSSFLYGGKVFSHANYYFWVPLVIPLFGGIFGLFLYKY
FVPH 
 
>Tsu AQP1 
MSSEPVNVHRYTAEGDRSGLKDRHGKTCEVCVGDESAAAVPSAVYNPQEQSGDGPEVKAGGGEAEVQNAADVNNW
APRRLRLDYRDYMGEFLGTFVLLFMGNGVVATTMLDDGLGFLSITLGWGIAVTMGLYISLGTSCGHLNPAVTVAN
AVFGCFPWKKVAGYIAMQMLGAFVGAACAYGVFADLLKQHSGGLIPFGDKGFAGMFSTYPRDGNRLFYCIFGEFI
CTAMLLFCVSGIFDANNSPAKGHEPLAVGALVFAIGNNIGYATGYAINPARDFGPRLFSAILFGSEVFTAGNYYF
WVPLFIPFLGGIFGLLLYKYFVPH 
 
>Tsu AQP2 
MQNQPDAMTHSTAVQMVNKNPEDGTGGADTERSDEMTAPTTRTGDAQKCETTNTPKEGAGGINYWAPRELRLKYR
DYMGELLGTFVLLLMGNGVVATVVVDGKLGFLSITLGWGIAVTMALYISLGISSGHLNPAVTVGNAVFGDFPWRK
VPGYIAAQMFGAFLGAACAYGVFADLLKEYCGGKLLAFGAKGIAGVFSTYPKEANSVFACVFGEFICTAILLFCV
CGIFDPNNSPAKKHEPLAVGSLIFAIGNNIGYSTGYAMNPARDFAPRVFSALLLGGEVFSHGNYYFWVPLFIPFL
GAIFGLFLYKYFVPH 
 
Figure 1-figure supplement 2. The ratio of non-synonymous v synonymous (dN/dS) codon 
changes calculated for selected comparisons between T. brucei and T. suis AQPs. The ratios 
were calculated using a region of high confidence alignments from ~amino acid 60 
(highlighted in Figure 1-figure supplement 1) to the C-terminus. 















